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Abstract
Constrained peptides have been successful as therapeutics owing to the rigidity in their framework,
allowing them to have enhanced pharmacological properties. Apart from covalent bond-based
cyclization, constraints can be induced by cyclization using metal coordination. The metals Re and
99m

Tc are one of the few metals which have not been studied in great detail for their ability to

cyclize linear peptides. A tri-alanine sequence was employed in the peptide backbone due to its
ability to form stable helices. In addition, another tripeptide sequence RGD, which is recognized
by the integrin αvβ3, was also used. These tripeptide sequences flanked by unnatural amino acid
and synthetic chelating agent on the terminal ends, were cyclized using [Re(CO)3(OH2)3]+ to form
a 2+1 chelation complex. This involved chelation to the metal through a bidentate ligand, pyridyl
triazole acetic acid or 2,2’-bipyridine-4-carboxylic acid (synthetic chelating ligand), and a
monodentate ligand 3-Pyridyl alanine (unnatural amino acid) from N- and C- terminal
respectively. NMR spectroscopy was used to compare the changes in chemical shift between linear
and cyclic peptides. Specific changes in the NMR of cyclic peptide confirmed the formation of
2+1 chelation system. Circular dichroism spectroscopy was able to confirm the formation of a turn
into the linear peptide on cyclization. Variable temperature NMR spectroscopy suggested the
formation of a secondary structure by detecting intramolecular hydrogen bonding in the cyclic
peptide. Lastly, the linear peptide pyta-Ala-Ala-Ala-3Pal was successfully radiolabeled using
[99mTc(CO)3(OH2)3]+. Linear peptides were successfully cyclized through

99m

Tc/Re(CO)3, thus

creating metal foldamers where the metal acts as the central core around which the turn occurs.

Keywords – Rhenium, technetium, cyclic peptides, metal clips, 2+1 chelation.
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Summary for Lay Audience
Peptides have increasingly garnered attention as a targeting component for molecular imaging
probes due to cumulative factors such as low molecular weight, small size and their ease to
synthesize. They display good tumour to background ratio and showcase the ability of having a
variety of bifunctional ligands attached to its C and N terminus. However, there are number of
disadvantages associated with having linear peptides as the targeting entity, such as their poor in
vivo stability and reduced specific binding.
Structural constraints, through cyclization of peptide backbone, can resolve some of the difficulties
seen with short linear peptides. Cyclic peptides have improved stability and targeting affinity
compared to their linear peptide counterparts. Owing to a locked conformation, cyclic peptides
maintain a desirable secondary structure which results in higher binding affinity. Apart from
covalent bond-based cyclization, cyclization can also be induced through metal coordination.
Metal complexes are known to stabilize peptide sequences. A turn can be induced within a peptide
backbone by metal coordination where the metal acts as a central core around which, a turn occurs.
99m

Tc is used in 80 % of all nuclear medicine procedures worldwide. However, 99mTc is a short-

lived radioisotope which is used in sub-microgram scale. This makes standard spectroscopic
characterization quite difficult. Rhenium and technetium belong to the same group of the periodic
table and therefore have similar physical and chemical properties. Hence, rhenium is used as a
non-radioactive analogue.
The research focuses on cyclization of linear peptides by 99mTc/ Re(CO)3+ coordination through
the use of a mono and a bidentate ligand. Pyta and 2,2’-bipyridine-4-carboxylic acid were used as
bidentate ligand along with 3-pyridyl alanine as a monodentate ligand. The cyclic and linear
peptides were characterised by various spectroscopic methods, which suggested a change in
conformation upon cyclization. This was especially observed for peptides with pyta as a ligand,
suggesting formation of a secondary structure. Thus, an innovative approach of introducing
structural constraints through metal-based cyclization is described. This approach would provide
a new direction for creating imaging agents, where a medically relevant metal is incorporated into
a peptide structure.
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Chapter 1
Introduction
Molecular imaging can be broadly defined as the in vivo visualization, characterization and
measurement of biological processes at the molecular and cellular levels.1 It is an exciting field of
research that has a wide range of applications which includes diagnostics, drug discovery and
development, theragnostic and personalized medicine. Based on its enormous potential, it has been
viewed as an important means of exploring the inner workings of the body in both normal and
disease states.2
The technique involves use of a molecular imaging probe to determine the expression of indicative
molecular markers at different stages of diseases and disorders. An ideal imaging probe should
have high binding affinity and specificity for a particular receptor, rapid clearance from non-target
tissue, high target to background ratio, low toxicity and immunogenicity, high in vivo stability and
easy production.3 Considering all of these requirements, the design and development of molecular
imaging probes is a challenging endeavor. A typical targeted imaging probe consists of a targeting
entity which enables site specific delivery of the probe to the diseased tissue, and a labelling moiety
which permits external detection of the target (Figure 1.1).

Figure 1.1 Scheme of a molecular imaging probe

Targeting entity
A targeting entity is a component of an imaging probe which has high affinity for the biological
target and selectively binds in much higher concentration to the diseased state than the surrounding
healthy tissue. It is quite important to select a targeting entity that can enable a high target to nontarget ratio, thereby increasing the contrast in the image, as well as the precision and accuracy in

diagnoses.4 Depending on the desired target, the targeting entity can vary between small
molecules, peptides and monoclonal antibodies. Several strategies have been employed to use
small molecules and macromolecules like monoclonal antibodies and antibody fragments to
accurately diagnose disease, but these efforts have been largely unsuccessful due to their low
specificity (small molecules) or limited target permeability (antibodies).
Peptides on the other hand have achieved significant success in their role as a targeting entity due
to desirable properties like favorable pharmacokinetics, improved binding affinity and selectivity,
better imaging ability as well as biosafety.4 Peptides are easy to synthesize and can be structurally
modified to enhance their pharmacokinetic properties. A variety of bi-functional chelating agents
can be attached at the C and N terminal of the peptide. They can also be labelled with radiometals
and optical agents, allowing for use with a variety of imaging modalities.5,6,7 An increasing number
of peptides, such as somatostatin (SST) peptide, vasoactive intestinal peptide (VIP), Arg-Gly-Asp
(RGD) peptide, and bombesin/gastrin-releasing peptide (BBN/GRP), have been successfully
characterized for tumor receptor imaging.8,9,10,11,12,13 Although peptides have many desirable
properties which gives them an edge compared to other targeting entities, they have many
disadvantages as well. The main concern over the use of linear peptides is their short biological
life due to enzymatic degradation. In addition, linear peptides have high flexibility in their
backbone which allows them to bind to multiple binding sites and as a result they have reduced
specificity towards the biological target.14 Therefore, in order to use peptides as targeting entities,
optimization is required.
The obstacles faced by linear peptides in terms of their biological stability and reduced specificity,
can be overcome by introducing structural constraints or by employing the use of peptidomimetics.
Peptidomimetics are molecules designed to mimic peptides in 3D space and retains their binding
and biological (agonist/antagonist) activity. This design entails alteration in the peptide backbone
or incorporation of an unnatural amino acid which reduces the rate of enzymatic degradation and
thereby enhances their in vivo stability.15,16 In addition, alteration of the N- and C- termini and
head to tail cyclization are methods used for resisting degradation by exopeptidases, an enzyme
known to specifically hydrolyze the N- and C- termini of the linear peptide.14 Structural constraints
can be employed to induce cyclization of small linear peptides, which aids in restricting the flexible
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nature of the peptides and enhances in vivo stability. The rigid geometry of the cyclic peptide leads
to enhanced binding affinity and specificity to the biological target.17

Solid phase peptide synthesis
Peptides can be synthesized by either solution phase or solid phase peptide synthesis methods. The
solution phase approach is an efficient method and can be used for synthesis of linear peptides in
a large scale. However, isolation, purification and characterization steps are required after the
addition of each amino acid, which makes it a rather time-consuming technique. Solid phase
peptide synthesis is a technique introduced by Merrifield in 1973.18 It can efficiently synthesize
large and more complex peptides. In this technique, peptides are synthesized in a stepwise manner
from C to N terminus, where the C terminus is attached to an insoluble resin. This allows the use
of excess reagents which ensures the complete addition of each amino acid. The reagents and the
by-products formed in this technique are soluble and can be easily removed by excess washing
and filtering without affecting the peptide which remains attached to the resin. This eliminates the
need of purification after each coupling step.
SPPS uses two strategies depending on the protecting groups 9- fluorenyl methoxycarbonyl
(Fmoc) or tert-butoxycarbonyl (Boc). Both of these strategies involve orthogonal protecting
groups which allow only the N terminal amino acid to be deprotected selectively before the
addition of the next protected amino acid, while the other side chain amino acids in the peptide
sequence remain protected. The Fmoc group is base labile and can be removed using piperidine
whereas the protecting groups on the side chains of the amino acid residues and the resin are acid
labile. Once the Fmoc group is removed, the next amino acid in the sequence is added along with
the coupling reagent and a base, N, N-diisopropylethylamine (DIPEA) in DMF. This cycle is
repeated until the desired peptide sequence is achieved. The peptide is then cleaved from the resin
using trifluoroacetic acid (TFA) along with triisopropyl silane (TIPS) which is used as a
carbocation scavenger (Figure 1.2) The cleaved peptide is purified using reverse phase high
performance liquid chromatography (RP-HPLC) and characterized by mass spectroscopy (MS).
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Figure 1.2 Solid phase peptide synthesis (SPPS) using 9-fluorenylmethoxycarbonyl (Fmoc)
strategy

Structural constraints through cyclization
Short peptide sequences often face entropic penalty for folding in their bioactive conformation
because of the flexibility in the linear structure. In addition, peptides readily undergo proteolytic
degradation, which affects their in vivo stability. These two problems can be overcome by a
number of structural changes, including the use of D-amino acids, backbone alterations (by Nmethylation or use of amide bond isosteres), use of non-native /unnatural amino acids or
cyclization strategies.19 Cyclization limits conformational flexibility of the macrocyclic structure
4

and thus, improves their favorable binding properties as well reduces the entropic penalty upon
binding.20 Cyclization can be introduced through various strategies like head to tail cyclization,
side chain to side chain cyclization or through formation of a disulfide bond between side chains
of amino acid (Figure 1.3).

Figure 1.3 Various types of peptide cyclization
Myelin based protein (MBP) is an example of a peptide cyclized by head to tail cyclization (Figure
1.4a). Cyclization of the linear peptide leads to the formation of an enhanced pharmacological
agent. Cyclic MBP shows better in vivo stability and efficacy compared to its linear epitope. This
epitope is a self-antigen and is known to stimulate CD4+ T cells.21 CD4+ T cells are T-helper cells
which help in triggering the body’s response to infections and thus are significant in achieving
regulated effectual immune response towards pathogens. A study by Gurrath et.al, states the
importance of cyclization for increased activity of the RGDFDV peptide sequence22 (Figure 1.4 b).
Integrin αvβ3 recognizes the tripeptide sequence RGD. Integrins are heterodimeric transmembrane
proteins responsible for linking the cells to extracellular matrix. It is composed of two
noncovalently associated glycoprotein subunits called α and β. There are 18 α and 8 β units that
can bond non covalently to form 24 different pair of integrins. The integrin αvβ3, α5β1, αvβ6 are
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present in lower concentration in normal tissues but are overexpressed in tumor cells, making them
critical for tumor angiogenesis.23
The study observed that cyclic peptide RGDFDV sequence had more potency than the linear
peptide due to the constrained geometry induced by head to tail cyclization. This makes it more
suitable to mimic the conformation required to bind to the receptor.

a

b

Figure 1.4 Structural constraints introduced through head to tail cyclization, a) MBP, b) Cyclo
(Arg-Gly-Asp-DPhe-Val)
Linear peptides constrained through cyclization can alter the specificity of the cyclic peptides to
different isoforms or subtypes of targeted receptors. This was demonstrated by a structure- activity
study conducted by Pfaff et al., in which the binding affinity of 16 cyclic RGD peptides were
compared to the linear GRGDS and RGDFv peptides with respect to several different integrin
receptors. Out of all the peptides compared, the cyclic RGDFv had a 3.3-fold greater binding
affinity (IC50 = 11.3 μM) to soluble αvβ3 and a 5.8-fold greater binding affinity (IC50 = 0.4 μM) to
immobilized αvβ3 compared with the linear RGDFv peptide. Interestingly, the linear RGDFv
showed a 1.3-fold and 1.5-fold better binding affinity to the soluble and immobilized αIIbβ3
integrin, respectively, compared with the cyclic RGDFv. Thus, this study showed that the fixed
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geometry created by cyclization of RGDFv sequence made it more specific to αvβ3 compared with
its linear counterpart.24

Cyclic peptides show enhanced inhibitory properties when compared to their linear derivatives.
This was demonstrated in a study conducted by Pakkala et al., which focused on the activity and

stability of linear and cyclic human glandular kallikreain (KLK2)-targeting peptides with the
sequences ARRPAPAPG (KLK2a) and GAARFKVWWAAG (KLK2b). The KLK2 protein is a
highly prostate-specific serine protease that can be inhibited to reduce the metastasis of prostate
cancer. Enhanced KLK2 inhibition was observed for disulfide-cyclized derivatives of the KLK2b
sequence compared with the linear sequence while the cyclic KLK2a peptides were all inactive.25

Metal co-ordination
Cyclization can also be induced by metal coordination. Various metals like copper, palladium and
iridium have been employed for cyclization of peptides.26,27,28 Nearly one-third of proteins have
metal coordination sites to execute regulatory or enzymatic processes since metal chelation is
commonly used for the control of protein quaternary structure.29
Metals are known for stabilizing peptide turns. This approach involves use of metal ions that ‘clip’
two or more ligating side chain functional groups of the peptide. In a study by Ghadiri et.al, Cd2+
showed similar stabilizing effects for peptide sequence Ac-AEAAAKEAAAEX1AAAX2A-NH2
which had (i, i + 4) spaced X1= Cys, X2= His ligating residues whereas Cu2+ stabilized the same
peptide sequence when X1= His, X2= His. This coordination led to the formation of a macrocyclic
bidentate complex which concurrently fixed the peptide backbone in an α-helical conformation.30
In a study by Giblin et. al, radiometals

99m

Tc and 188Re were shown to cyclize α-melanocyte

stimulating hormone (α-MSH) which simultaneously provided potential use as an imaging agent
and a radiopharmaceutic.31 α-MSH is a tridecapeptide [Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-ArgTrp-Gly-Lys-Pro-Val-NH2] that regulates skin pigmentation in most vertebrates, where the core αMSH sequence His-Phe-Arg-Trp is sufficient for receptor recognition. Improved chemical
stability and bioactivity were observed for the cyclic peptide along with superior receptor-binding
properties in comparison to their linear counterparts. Biodistribution and tumor-targeting studies
of the corresponding 99mTc complex in melanoma-bearing C57 mice showed rapid tumor uptake
and significant tumor retention.31
7

A similar study conducted by Cheng et.al involved the development of an iodinated α-MSH
peptide Ac-[D-Lys2 (125I-IBA), Arg11]-ReCCMSH (Figure 1.5). This peptide sequence consisted
of three important components namely ReCCMSH(Arg11), which is the receptor targeting
component resisting proteolytic degradation, D-Lys which is the residue for label conjugation and
IBA (iodobenzoate) label for reducing the dehalogenation in vivo. On comparison with the radioiodinated linear version, the rhenium cyclized radio-iodinated α-MSH analogue showed higher
retention, tumor uptake and biodistribution.32 This emphasized that metal cyclization enabled high
tumor uptake and retention which invariably translates to improved tumor imaging contrast as well
as effective therapy at lower doses, sparing the non-target tissues.

Figure 1.5 Structure of Ac-[D-Lys2 (125I-IBA), Arg11]-ReCCMSH

Imaging entity
The imaging entity is the part of an imaging probe that allows for external detection of the probe
localization. There exist several imaging modalities, depending on the type of biological process
one needs to visualize and the type of imaging data one wants. More commonly used imaging
modalities include computed tomography (CT), magnetic resonance imaging (MRI), positron
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emission tomography (PET), single photon emission computed tomography (SPECT), and
ultrasound (US).
SPECT and PET are radionuclide imaging modalities that enable the evaluation of biochemical
changes and the level of molecular targets in the living subject. Although both these techniques
have diagnostic advantage over other classical imaging modalities, they have limitations as well.
Both of these modalities use ionizing radiation and there are limitations on how many scans a
subject can undergo in a year. A very small amount of imaging agent is required for both
18

PET/SPECT, which is advantageous as it is unlikely to cause any pharmacological effects.2 F
64

76

(t1/2 = 109.8 min), Cu (t1/2 = 12.7 h), and Br (t1/2 = 16.2 h), or ultra-short lived radionuclides
11

13

such as C (t1/2 = 20.3 min), N (t1/2 = 10 min), and 15O (t1/2 = 2.04 min), are the radionuclides
most commonly used for PET imaging. These nuclides decay by positron emission.

Single photon emission computed tomography
Single photon computed emission tomography (SPECT) is one of the widely used imaging
modalities. SPECT employs radionuclides such as

99m

123

111

Tc (t1/2 = 6 h), I (t1/2 = 13.3 h), and In (t1/2

= 2.8 days). The emission energy emitted by these radionuclides ranges between 100 and 300 keV
which is sufficient to pass through the body and be detected externally but does not cause harm to
the patient. Unlike PET imaging, radionuclides employed by SPECT emit γ rays, which can be
detected directly. The gamma camera in a SPECT scanner rotates 180° or 360° around the patient
compared to the detector in a PET scanner, which is stationery. Since the radionuclides used by
SPECT imaging is different than PET, the set up required by it to construct and collect the data is
completely different than PET 33 (Figure 1.6).
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Figure 1.6 SPECT imaging machine
Despite of poor resolution and sensitivity, SPECT is cost effective in comparison with PET due to
the fact that majority of the radionuclides can be produced using a generator and have a longer
half-life. However, the poor resolution and sensitivity can be overcome by combining SPECT with
CT. This makes SPECT a more attractive and accessible imaging modality compared to PET.

Technetium-99m as signaling source for SPECT
99m

Tc is a decay product of molybdenum-99 (Mo-99) and is synthesized using a generator. It is

used in 80 % of all nuclear medicine procedures worldwide. It has many favorable qualities,
including: 1) easy availability, ii) low cost, iii) easy handling, iv) good imaging characteristics,
and v) absence of strong radiation such as α and β decay. This makes it an isotope of choice for
99m

SPECT imaging.

Tc has a half-life of 6 hours, which makes it suitable for radiolabeling

biomolecules, as well as acquiring images. Several
(sestamibi, Cardiolite®),
Ceretec®) and

99m

Tc radiopharmaceuticals like

Tc-tetrofosmin (Myoview®),

99m

99m

Tc-MIBI

99m

Tc-HMPAO (exametazime,

Tc-ECD (bicisate, Neurolite®) have found clinical application as widely used

99m

cardiac and brain imaging agents.34
99m

Tc is an artificial element obtained from

99

Mo/99mTc generator where

99

Mo decays to

99m

Tc

through β decay. 99mTc is the metastable form of 99Tc and decays back to 99Tc by emitting a γ ray
with an energy equal to 140 keV (Figure 1.7). The γ emission can be detected by Single Photon
Emission Computer Tomography (SPECT).
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Figure 1.7 Decay scheme of 99Mo to 99Ru
The 99Mo/99mTc generator is a simple apparatus composed of an alumina column. 99Mo is absorbed
on this column in the chemical form of molybdate [99Mo]MoO4-2. 99Mo decays into 99mTc which
leads to formation of pertechnetate [99mTc]TcO-. The single negative charge on the pertechnetate
makes it less tightly bound to the alumina in comparison to the double negatively charged
molybdate. The [99mTc]NaTcO4 can be easily eluted from the column with a saline solution. This
becomes possible due to the depression caused by an under-vacuum vial, which is inserted in the
pertechnetate collecting area 35 (Figure 1.8).
99m

Tc is produced in the form of pertechnetate (99mTcO4)- from the generator where its oxidation

state is +7. In order to be linked to a bioactive molecule, 99mTc(VII) has be reduced to a suitable
oxidation state in presence of suitable ligands. 99mTc exists in oxidation states ranging from -1 to
+7. Clinically relevant compounds containing

99m

Tc with oxidation states of 0, +2, +6 have not

been studied in greater detail. 99mTc is most stable in its +4 and +7 oxidation states and exist in the
form of oxides, sulfides, halides and pertechnetates.
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Figure 1.8 Schematic of a 99Mo/99mTc generator
One of the most extensively studied metal fragment for technetium is the Tc(V) oxo core. Various
examples have been studied where Tc(V) is stabilized by oxo groups and contain oxo technetium
(Tc=O) core like TcO3+, trans-TcO2+, trans-[Tc2O3]4+. This moiety is penta-coordinate and
contains an axial oxo group.36
[99mTc(CO)3]+ is a versatile building block for variety of biomolecules. This moiety consists of
technetium coordinated to three carbonyl groups, in +1 oxidation state. [99mTc(CO)3]+ core is
typically inert and is air and water stable. Compared to
ligand is limited,

99m

Tc(V)-oxo form where the choice of

99m

Tc(I) core can be coordinated to almost any bidentate, monodentate and

tridentate donor ligands. The carbonyl groups are known to stabilize the metals by increasing the
sigma donation of the metal center as a result of π back bonding.37 [99mTc(CO)3]+ can be easily
synthesized in the triaqua form [99mTc(CO)3(H2O)3]+ from 99mTcO4- by using an Isolink kit. The
Isolink kit contains sodium tartrate, sodium tetraborate, sodium bicarbonate, sodium
boranocarbonate, which acts as a carbonyl source and reduces pertechnetate from +7 oxidation
state to +1 state. This reaction was first reported by Alberto et.al and was carried out at 90° C for
10 minutes.38 Pitchumony et al. optimized this reaction by carrying out a microwave assisted
synthesis which reduced the reaction time to 3.5 mins at 110° C.39 This leads to the formation of
an octahedral complex with the carbonyls trans to the aqua ligand creating a facial orientation.
[99mTc(CO)3(H2O)3]+ complex has very good solubility and stability over a broad range of ph. The
aqua molecules achieve more lability due to the trans effect of the facial carbonyl groups and are
thus an easy target to be replaced by a variety of donors including carboxylic acids, phosphines,
12

thiols, thioethers, amines or amides as monodentate, bidentate or tridentate ligands. The resulting
complexes achieve kinetic stability due to the d6 low spin configuration.40

Rhenium Analogues
99m

Tc is a short-lived radioisotope and is thus used in sub-microgram scale. This makes standard

spectroscopic characterization quite difficult. Hence, in order to study the coordination chemistry
of technetium, there is a need for a non-radioactive analogue. Rhenium and technetium belong to
the same group of the periodic table and therefore have similar physical and chemical properties.
Belonging to the same group, rhenium is quite comparable to technetium in its size, shape, formal
charge and lipophilicity. 6,41 Rhenium (185/187Re) is a therefore a good analogue to study

99m

Tc

coordination chemistry where 187Re (62.6 %) and 185Re (37.4 %) refers to the two stable isotopes
of rhenium. It is quite easy to synthesize and characterize larger quantities of rhenium complexes
prior to radio-labelling with 99mTc. [99mTc(CO)3(H2O)3]+ is quite easy to prepare using the Isolink
kit in a microwave synthesizer, but the same method cannot be used for the synthesis of the
rhenium analogue [Re(CO)3(H2O)3]+. This is due to the fact that rhenium is more inert, slower to
react and harder to reduce than technetium.38
Furthermore, the application of Re(CO)3+ is also extended to fluorescence imaging for complexes
having appropriate aromatic donor ligands, since luminescent probes containing Re(I) have been
described as being useful for the in vivo study of biological processes. This was demonstrated by
Bartholoma et.al, where complimentary pairs of fluorescent and radioactive probes were
synthesized to exploit the properties of 99mTc(CO)3+ and Re(CO)3+ cores. The study demonstrated
the use of single amino acid chelate (SAAC)-type ligand bis(quinoline-2-methyl)-N-α-Fmoc-llysine (Figure 1.9). This complex was incorporated in the tetrapeptide fMLF, a targeting sequence
used for formyl peptide receptor for neutrophils. The Re(CO)3+ complex of this SAAC-type ligand
displayed desired fluorescence and the

99m

Tc(CO)3+ complex displayed stability in aqueous

solution. This approach provided direct correlation between in vitro and in vivo imaging agents
and proved to be instrumental in the development of complimentary in vitro fluorescent and in
vivo radiopharmaceutical probes.42
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Figure 1.9 SAACQ; the metallated derivative fMLF[Re(CO)3–SAACQ]G42
Metal complex incorporated in an integrated fashion, forms a crucial part for ligand-receptor
interaction. Though, this is usually rare for peptide-based technetium radiopharmaceuticals as
metal complexes are typically incorporated in a pendant fashion far away from the active binding
site to avoid interference with the area of ligand-receptor interaction. A study by Bigott-Hennkens
et.al reported the cyclization of the octreotide peptide by successfully replacing the disulfide
bridge function through the coordination of Re(V) oxo inorganic core directly to the octreotide
peptide backbone.43 The metal complex, although not located in the receptor binding pocket, was
instrumental in binding due to formation of a cyclic constraint. This concept was also demonstrated
in a study conducted by Rosita et.al, where rhenium tricarbonyl complex was coordinated to
cyclopentadienyl moiety and then incorporated into the peptide ghrelin 44 (Figure 1.10). Ghrelin is
a 28 amino acid peptide hormone with a unique lipophilic n-octanyl post translational modification
in its serine-3-residue. It is known to be the endogenous ligand for the GHSR (growth hormone
secretagogue receptor). Cp99mTc(CO)3 complex was chosen as a good candidate because in
addition to being small in size, chemically and metabolically stable and neutral, it was most
importantly lipophilic in nature which is a key requirement for the ghrelin side chain. 185/187Re was
used in place of 99mTc for chemical and biological analysis. It was observed that the binding affinity
of the CpRe(CO)3 complex suitably improved due to the incorporation of the metal complex. The
key component of this success was due to the mimicking of ghrelin side chain by CpRe(CO)3. This
study formed the first example of incorporating rhenium into a peptide structure where the metal
complex formed a crucial part for binding.44
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Figure 1.10 Rhenium tricarbonyl bearing Ghrelin (1-14)44

Technetium-99m radiopharmaceuticals
Peptide based technetium-99m radiopharmaceuticals are generally composed of a peptide for
targeting, the radiometal for external detection, and a chelator to attach the metal to the peptide.
Several biologically relevant peptides have been studied in the literature ranging from somatostatin
analogues, bombesin, octreotide, neurotensin and Arg-Gly-Asp peptide moiety. A significant fact
about 99mTc radiopharmaceuticals is that the [99mTc (CO)3]+ complexes can be stabilized either by
a tridentate chelator, a ‘2+1’ chelation system, or three mono-dentate ligands. A ‘2+1’ chelation
system is the combination of bi-dentate and mono-dentate ligands attached to a metal. Apart from
the pendant fashion, the metal complex can also be added to the peptide in an integrated design
where the metal is incorporated into the backbone of the peptide. This design hides the metal in
the molecule, minimizing interference with binding of the biomolecule to the receptor, and in some
cases is an integral component in locking the peptide in its active form, making the metal
imperative for biological activity.45

Goal of the study
Previously in our lab, a turn conformation was reported by E. Simpson, which was created by
coordinating the linear pentapeptide Ac-HAAAH through

99m

Tc/Re(CO)3.45 A 2 + 1 chelation

system was formed through the bidentate chelation of the imidazole nitrogen and carboxyl oxygen
at one end and monodentate chelation of the imidazole nitrogen at the other end (Figure 1.11).
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Figure 1.11 Pentapeptide Ac-HAAAH synthesized by Simpson et.al 45
Although the effort to cyclize the pentapeptide was successful, histidine having multiple
coordination sites led to the formation of coordination isomers.45 To mitigate this problem, a better
chelator was proposed, which has fewer coordinating sites and can form a favorable ring size with
the metal. This led to the use of unnatural amino acids and synthetic ligands as metal chelators. A.
Patel demonstrated the cyclization of the biologically relevant peptide RGD having the unnatural
amino acid 3-pyridyl alanine at the C terminus and the ligand pyridyl triazole at the N terminus.46
This formed a 2+1 chelation system, suggesting that an improved metal complex was discovered.
Our current goal is to use the same principle and synthesize a linear peptide sequence AAA with
unnatural amino acids and ligand at its terminal ends. In addition, we will also be synthesizing the
biologically relevant peptide RGD with a different ligand at its N terminus. Thus, we aim to cyclize
these peptides through 99mTc/Re(CO)3 where the metal acts as the central core around which the
turn occurs (Figure 1.12).

Figure 1.12 2+1 coordination using an integrated design.
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Chapter 2

2

Optimization of cyclization reaction of linear peptides with
rhenium tricarbonyl metal core.
Introduction

Cyclic peptides are known to exhibit enhanced in vivo stability and specificity over their linear
counterparts. As a result of structural modification, cyclic peptides can mimic the geometries of
the biologically active parts of large endogenous proteins. This enhances their binding affinity
towards the receptor compared to the linear peptides of the same sequence. Depending on the type
of cyclization and the position of cyclization, constrained peptides with different biological
activities can be generated.1
Apart from cyclizing peptides by lactonization, lactamization or formation of a disulfide bridge,
metal coordination can be used as an external means for inducing peptide cyclization. The amino
acid side chains of the peptides usually have the ability to be used as ligands to coordinate the
metal complex. These ligands chelate the metal which creates a turn in the structure and thus
cyclizes the linear peptide. Metal used for cyclization of peptides can influence the secondary
structure of the proteins. This was seen in a study by Natale et.al where the native prion protein
(PrP) was selectively bound to Cu (II) through the chelation of the four histidine residues.2 Prion
protein is a small, cell surface glycoprotein which is responsible for pathogenesis of
neurodegenerative disorders called prions diseases.3 It was the geometrical coordination
preferences of the metal along with the stability of the chelate ring formed that forced the
coordinated amino acids to adopt a fixed rigid conformation.
Previously in our lab, natural amino acids were used as ligands to coordinate with the group 7
transition metals Re and radioactive 99mTc, forming 2+1 chelation systems. A 2+1 chelation system
is comprised of a metal complex with coordination to both a bidentate and a monodentate ligand.
Simpson et.al cyclized the pentapeptide Ac-HAAAH-OH using the fac [Re(CO)3(OH2)3]+ core
with histidine as the as the metal chelator.4 Histidine was chosen as the natural amino acid ligand
due to its high biological stability along with its ability to coordinate rapidly and quantitatively in
low concentration. In addition, several studies have observed the ability of histidine to coordinate
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with different metal centers in metalloproteins like copper in hemocyanin,5 iron in hemoglobin,6
and zinc in thermolysin.7 The imidazole of the histidine on the N-terminus of the pentapeptide was
used as a monodentate chelator and the imidazole and carboxylic acid of the histidine at the Cterminus were used as a bidentate chelator to form a 2+1 chelation system. This chelation system
was used to coordinate Re/99mTc(CO)3+ and form a cyclic peptide. Although the peptide cyclization
attempt was successful, there was formation of numerous linkage isomers due to the multiple
coordinating sites on histidine. Linkage isomers are two or more coordination compounds which
differ by the donor atom of at least one of the ligands. Imidazole on histidine can coordinate to the
metal through N1 and N3 atoms which leads to formation of 7 or 8 membered ring at the Cterminus and a 6 membered ring at the N- terminus (Figure 2.1). Therefore, there was a need for a
better chelator that had fewer coordinating sites and can form a stable ring size on coordination
with the M(CO)3 core.

a.

b.

Figure 2.1 a) Rhenium coordination at C-terminal forming 7 or 8 membered ring, b) rhenium
coordination at N- terminal forming 6 membered ring.
In order to reduce the number of linkage isomers formed and to enable the formation of a stable
ring size with the metal, Patel et.al proposed the use of unnatural amino acids and synthetic ligands
as metal chelators.8 Pyridyl triazole acetic acid (pyta) and 3-pyridyl alanine (3-Pal) were proposed
to be used as bidentate and monodentate ligands respectively whereas the tri-alanine sequence was
replaced with the Arg-Gly-Asp to create a biologically relevant peptide. The peptide sequence
pyta-RGD-3Pal was then coordinated to the fac Re(CO)3 core, creating a 2+1 chelation system.8
However, the isomers of this coordinated peptide were not studied or discussed in detail.
Furthermore, the reaction conditions used for the cyclization of the linear peptide by Simpson et.al
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and Patel et.al resulted in low yields of the cyclic product. It was thus essential to optimize the
cyclization reaction conditions which would bear high yield of the cyclic product.
The overall goal of this chapter is to optimize the cyclization reaction conditions and translate the
success of the unnatural amino acids and different synthetic ligands as metal chelators on to the
model system of Xaa-Ala-Ala-Ala-Xaa (Xaa= unnatural amino acid or synthetic ligand).

Results and Discussion
To optimize the reaction conditions of the coordination reaction, we needed to first synthesize the
linear peptides. We chose the model peptide sequence pyta-Ala-Ala-Ala-3Pal for the optimization
study. The linear peptide was designed to have two terminal chelators capable of coordinating
rhenium, as well as three central alanine residues to aid in forming a turn in the peptide upon
coordination. This would allow the peptide to coordinate the rhenium in a [2+1] fashion using the
N-terminal and C- terminal chelator, resulting in a neutral peptide-metal complex. Chelation of the
peptide to the metal was done using ligand pyridyl triazole acetic acid and unnatural amino acid
3-pyridyl alanine. Pyridyl-triazole would coordinate to Re(CO)3+ in a bi-dentate fashion whereas
3-pyridyl alanine can be used to chelate the metal in a monodentate fashion. Pyridyl triazole acetic
acid and the methoxy ester of 3-pyridyl alanine were synthesized as shown in the Scheme 2.1 and
Scheme 2.2 respectively.

Scheme 2.1 Synthesis of pyridyl triazole acetic acid 9, 3
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Scheme 2.2 Esterification of 3-pyridyl alanine, 4
Synthesis of linear peptides can be done using the solid phase or solution phase peptide synthesis
method. Solid phase peptide synthesis is an efficient method for synthesizing peptides on a small
scale but when it comes to scaling up the production, it can become quite expensive. This factor
led us to shift our attention to solution phase peptide synthesis. Though a more tedious method,
solution phase peptide synthesis can be a comparatively less expensive option for bulk production.

Solution phase peptide synthesis
Peptide sequence pyta-Ala-Ala-Ala-3Pal-OMe was synthesized from the C-terminus unnatural
amino acid 3-pyridyl alanine carboxylic acid. 3-Pyridyl alanine was esterified using methanol to
protect the C-terminal carboxylic acid10 (Scheme 2.2). It was then coupled to a tert-butoxycarbonyl
(Boc)-protected alanine using coupling agents HOBt (1-hydroxybenzotriazole hydrate), HBTU (2(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) in presence of a base
TEA (triethyl amine) in dichloromethane. The coupling was followed by removal of the Boc group
using trifluoroacetic acid in dichloromethane to yield a free amine. This free amine was then
coupled with an incoming Boc-protected alanine. This process was followed by a series of
deprotection and coupling steps till the desired peptide sequence Ala-Ala-Ala-3Pal-OMe was
achieved. The last stage of peptide deprotection was followed by coupling with the ligand pyridyl
triazole acetic acid in a similar manner (Scheme 2.3). Though the coupling of the ligand to the
peptide sequence was successful as confirmed by LCMS characterization, purification of the
peptide after the last coupling proved to be challenging. Several attempts made to isolate the linear
peptide from the mixture of the starting materials and salts proved to be unsuccessful which led us
to switch back to solid phase peptide synthesis.
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Scheme 2.3 Synthesis of linear peptide sequence pyta-Ala-Ala-Ala-3Pal-OMe, 2.4 using solution
phase peptide synthesis

Solid phase peptide synthesis of pyta-AAA-3Pal, 3.1
The linear sequence of pyta-AAA-3Pal was synthesized by standard Fmoc solid phase peptide
synthesis method. Rink amide resin (MBHA) was used as a solid support and the peptide was
synthesized from C to N terminus. Each amino acid was vortexed with the coupling agent HCTU
(2-(6-chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium

hexafluorophosphate),

base

DIPEA (diisopropyl ethyl amine) in DMF for 10 mins prior to coupling. The N-terminus was
coupled with the ligand pyridyl triazole acetic acid (pyta) which was synthesized according to
previously published method,7 (Scheme 2.1). The tert-butyl group on the ligand was removed by
a method published by Lim and Storr et al.8 Pyta was vortexed for 10 mins with coupling agent
TSTU (O-(N-succinimidyl)-1,1,3,3-tetramethyl uronium tetrafluoroborate), DIPEA in DMF to
form a pre-activated ester prior to coupling with the tetrapeptide. Removal of all protecting groups
and cleaving of the resin was done with 95:2.5:2.5 TFA: TIPS: H2O. The peptide was precipitated
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with cold tert-butyl methyl ether (TBME), centrifuged, filtered and lyophilized to give crude linear
peptide of the desired sequence. The crude linear peptide was then purified by RP-HPLC.

Optimization of rhenium coordination reaction
Previously in our lab, Simpson et.al carried out the coordination reaction at room temperature in
the presence of the base NaOH.2 Replication of these conditions for the coordination of pyta-AAA3Pal resulted in a poor yield of the coordinated peptide. Patel et.al carried out the coordination
reaction using microwave conditions at 105º C for 1 hour.6 This reaction condition resulted in
formation of several by-products which could possibly be due to degradation of peptides at higher
temperature. The low yield obtained from both the reaction conditions prompted us to carry out an
optimization study to get suitable reaction conditions with maximum yield of the cyclic peptide.
Optimization was carried out by testing the coordination reaction at different temperatures and
time. Impact of solvent change and presence of a base was also examined.

Temperature and time optimization
Linear peptide sequence pyta-AAA-3Pal was used to study the effect of increasing temperature
and time during the coordination reaction. Rhenium coordination was carried out at four different
temperatures 0º C, RT, 50º C, 100º C respectively for 0-4 hour time points (Scheme 2.4), with
aliquots from the reaction being analyzed and quantified using UHPLC. Characterization by
UHPLC showed presence of one dominant peak (A) of the cyclic peptide along with two less
dominant peaks (B, C) having identical product m/z value as the dominant peak (Figure 2.2).

3.8

3.1

Scheme 2.4 Rhenium coordination of peptide sequence pyta-Ala-Ala-Ala-3Pal, 3.1
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Absorbance (AU)

A

B, C

Figure 2.2 UHPLC UV trace of cyclic peptide 3.8, showing dominant (A) and less dominant
conformer (B, C)
The data from the study was plotted in the form of a graph of total coordinated product vs time
(Figure 2.3). Total coordinated product constitutes a percentage ratio of the cyclic peptide to the
sum of the linear and cyclic peptide. Cyclic peptide consists of a combined sum of the dominant
peak of the cyclic peptide (A) along with two other less dominant peaks (B, C). These peaks could
be attributed as the conformer/isomer of the dominant peak. The optimization was carried out to
isolate the maximum percentage of the dominant peak (A).
It was quite interesting to observe that while the coordination took place at all four temperatures,
only the reactions carried out at 50º C and 100º C showed significant increase in the percentage of
the total coordinated product. Observation from the graph showed that the reaction carried out at
100º C formed higher percentage of total coordinated product within the first 30 mins of the
reaction compared to the reaction carried out at 50º C (Figure 2.3). However, the total coordinated
product seen at 100º C had maximum percentage of the isomer/conformer than the desired
dominant peak. As the reaction progressed at 100º C, more of the dominant peak was getting
converted to its isomer/ conformer state. This can be seen in the graph plotted for the % coordinated
peptide v/s time, where % coordinated peptide constitutes to the percentage ratio of dominant (A)
and the less dominant peaks (B + C) respectively to the sum of linear and cyclic peptide (Figure
2.4). The reaction at 50º C in comparison to 100º C, yielded maximum of dominant cyclic peptide.
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Over the course of two hours, least possible amount of the cyclic isomer/conformer was observed
at 50º C in addition to a better yield of the cyclic peptide.

Figure 2.3 Graph of total coordinated product vs time for the four different temperatures used for
synthesis of 3.8 (Scheme 2.4), where total coordinated product % = (cyclic peptide / linear
peptide + cyclic peptide) %
As a result, in order to maximize the yield of cyclic peptide and limit the formation of cyclic
isomer/conformer, the reaction conditions of 50º C for the time period of two hours seems optimal.

Figure 2.4 Graph of % coordinated peptide vs time for synthesis of 3.8, where % coordinated
peptide = [A or (B + C)/ linear peptide + cyclic peptide] %
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Optimization of reaction solvent
The rhenium coordination reaction was carried out in methanol instead of distilled water. It was
observed that while there was an increase in the yield of the total coordinated product, the yield of
the dominant conformer was lower when compared to the yield obtained with distilled water as
the solvent. This means that there was an increase in the yield of the less dominant conformer/
isomer over time in methanol.

Optimization using a base
Previously, the coordination reaction carried out by Simpson et.al and Patel et.al involved the
presence of a strong base, NaOH. Impact of the base was examined during the coordination
reaction by carrying out the reaction both in presence and absence of the base NaOH. The reaction
was performed at 50º C. It was observed that while the coordination took place both in presence
and absence of a base, there was a significant difference in the percentage of the cyclic product
obtained in the reaction carried out in presence and absence of base. The reaction performed
without the base gave better results in comparison to the reaction with base.

Conclusion
Optimization studies were performed to observe the reaction conditions required to improve the
efficiency of rhenium coordination reaction. This study was carried out at four different
temperatures in order to determine an optimal temperature and reaction time for the coordination
reaction. The solvent change from water to methanol and addition of a base both failed to increase
the yield of the cyclic peptide. The observations from the optimization experiments led us to
conclude that the rhenium coordination reaction carried out at 50º C for 2 hours in distilled water
without a base comparatively increased the yield of cyclic peptide.

Experimental data
All the reagents and solvents were purchased from Sigma Aldrich, Fisher Scientific, Alfa-Aesar,
Chem- Impex, Novabiochem, Oakwood Chemicals, Peptides International. The Boc-protected
amino acids were purchased from Chem-Impex International Ltd. and were used without further
purification. For analytical UHPLC-MS, studies were performed on a Waters, Inc. Acquity
UHPLC system combined with Xevo QToF mass spectrometer (ESI+, cone voltage = 30V). A
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Waters, Inc. Acquity UHPLC BEH C18 2.1 x 50 mm, 1.7 um column was used with a gradient
solvent system consisting of 0.1% formic acid in acetonitrile and 0.1% formic acid in water. NMR
spectroscopy was performed using Bruker Avance III HD 400 (B400) in deuterated dimethyl
o

sulfoxide (DMSO- d6) or CDCl3 at 25 C.

Small molecule synthesis
a) tert-butyl azido acetate, 1
A modified procedure was used.11 To a suspension of sodium azide (2.28 g, 35.07 mmol) in DMSO
(15 mL), tert-butyl bromo acetate (4.5 g, 23.07 mmol) was added. The resulting opaque white
color solution was stirred overnight at RT. This solution was diluted with 300 mL of distilled water
and the compound of interest was extracted using diethyl ether and concentrated to afford a
colorless oil (2.86 g, 78%) Characterization was identical to published values.10 1H NMR (400
MHz, CDCl3): δ 1.50 (s, 9H), 3.74 (s, 2H).
b) tert-butyl-2-(4-phenyl-1H-1,2,3-triazol-1-yl) acetate, 2
A modified procedure was used.9 tert-Butyl azido acetate, 1 (1.765 g, 11.23 mmol) and 2- ethynyl
pyridine (1.158 g, 11.23 mmol) was dissolved in isopropanol (2 mL) in a 20mL vial. In another 20
mL vial, copper (II) sulphate pentahydrate (0.140 g, 0.56 mmol) and L-ascorbic acid (0.989 g, 5.6
mmol) were dissolved in distilled water. The solids were completely dissolved by sonicating for
20 minutes at room temperature. The aqueous mixture was added dropwise to the stirring organic
mixture over 15 minutes. The resulting yellow turbid solution was allowed to stir overnight at RT.
The solution was diluted with chloroform (15 mL) and washed thrice with saturated EDTA
solution. The organic product was extracted from the aqueous layer using chloroform (2 x 20 mL).
The combined organic layers were dried over Na2SO4 and then concentrated to remove
chloroform. The crude product was purified by crystallization in methanol which afforded white
crystals of the mentioned compound. (1.96 g, 67 %) ESI-LCMS: m/z calculated for C13H17N4O2
1

261.1352; observed [M+H] 261.1306, H NMR (400 MHz, CDCl3): δ 8.58 (d, 1Hz, 1H), 8.25 (s,
1H), 8.18 (d, 3JH-H = 1.4 Hz, 1H), 7.78 (m, 1H), 7.23 (m, 1H), 5.12 (s, 2H), 1.49 (s, 9H).
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c) 2-(4-phenyl-1H-1,2,3-triazol-1-yl) acetic acid (Pyta), 3
tert-Butyl-2-(4-phenyl-1H-1,2,3-triazol-1-yl) acetate (1.3 g, 5.1 mmol), 2 was dissolved in a 1:1
solution of trifluoroacetic acid and dichloromethane. The resulting solution was allowed to stir
overnight at room temperature. After rotary evaporation of dichloromethane, compound of interest
was precipitated from the solution by using diethyl ether. This afforded a white color powder of 3.
(1.0 g, 96%) ESI- HRMS: m/z calculated for C9H9N4O2, 205.0726; observed [M+H]+ 205.0757,
1

H NMR (400 MHz, D2O): δ 8.58 (s, 1H), 8.05 (s, 1H), 7.91 (m, 1H), 7.36 (m, 1H), 5.36 (s, 2H).

d) 3-Pyridyl alanine methoxy ester, 4
A round bottom flask containing 15 mL of methanol was cooled in ice for 10 mins. Acetyl chloride
(1.40 mmol, 1 mL) was added dropwise to the round bottom flask. This was followed by the
addition of 3-pyridyl alanine dihydrochloride (6.01 mmol, 1 g). The cloudy reaction mixture was
refluxed overnight, following which the solvent was removed by rotary evaporation. This afforded
an off-white solid (1.08 g, 83%). This was further used for the coupling reaction and no further
purification was required. ESI-HRMS: m/z calculated for C9H13N2O2 181.0977; observed [M+H]+
1

181.1003, H NMR (400 MHz, DMSO): δ 8.90 (d, 3JH-H = 4.0 Hz, 1H), 8.86 (bs, 2H), 8.82 (dd,
3

JH-H = 8.0 Hz, 4.0 Hz, 1H), 8.44 (dt, 3JH-H = 8.0 Hz , 1.6 Hz, 1H), 7.96 (dd, 2JH-H = 8.0 Hz, 3JH-H =

5.2 Hz, 1H), 3.74 (s, 3H), 3.47-3.36 (m, 2H).
e) Tris-aqua tris-carbonyl rhenium (I) triflate, 5
Commercially available Bromo pentacarbonyl rhenium (1 g, 2.76 mmol) was added to dry
dichloromethane (20 mL) and kept for stirring. Silver triflate (0.894 g, 3.47 mmol) was weighed
under subdued light and was added to the flask under increased nitrogen flow. The flask was
covered with aluminum foil and the solution was allowed to stir at RT for 3h. The resulting white
turbid solution was gravity filtered to remove the precipitate of by-product salts, silver bromide.
The solution was concentrated to half its volume. Hexanes were degassed in a 50 mL round bottom
flask by bubbling nitrogen through for 30 minutes, following which the dry hexane was added
slowly to the rhenium pentacarbonyl triflate solution and allowed to crystallize to a white powder.
The white powder (0.835 g) was dissolved in distilled water (17.56 mL) to form 0.1 M solution
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and was refluxed overnight which afforded [Re(CO)3(OH2)3]+ solution.12 The resulting solution
was characterized by LC-MS. (ESI-MS)+ : m/z calculated for C5H7N1O5Re, [(M – H2O) + CH3CN]
347.9882; found 348.0110, calculated for C7H8N2O4Re, [(M – 2H2O) + 2CH3CN] 371.0042; found
371.0145; calculated for C9H9N3O3Re, [(M – 3H2O) + 3CH3CN] 394.0202; found 394.0366.
General procedure for Peptide synthesis (Solution phase)
Peptide was synthesized from C to N terminus with the 3-pyridyl alanine being esterified to protect
the carboxylic acid. The amine of the 3-pyridyl alanine was coupled with a tert-butoxycarbonyl
(Boc) protected amino acid where the Boc group is acid labile. The first coupling was carried out
using the coupling agent HOBt (1-hydroxybenzotriazole hydrate), HBTU (2-(1H-Benzotriazole1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) along with the base triethyl amine at room
temperature for 24 hours. The resulting solution was given washings with saturated sodium
bicarbonate, 10 % citric acid solution and brine to remove any excess base and acid. Purification
was done using column chromatography. This was followed by Boc group removal using 50%
trifluoroacetic acid in dichloromethane for one hour. This was followed by a series of coupling
using Boc protected amino acids and deprotection until the desired peptide sequence is obtained.
2.11.1

Boc-Ala-3-Pal-OMe, 2.1

3-Pyridyl alanine methoxy ester, 4 (1.07 g, 4.58 mmol, 1eq) was added to a round bottom flask
containing 20 mL of dichloromethane. This was followed by addition of the base triethyl amine
(10.07 mmol, 2.2 eq), HBTU (1.91 g, 5.04 mmol, 1.1 eq) and HOBt (0.68 g, 5.04 mmol, 1.1 eq).
The reaction mixture was allowed to stir for 10 minutes at room temperature, followed by addition
of Boc-Ala-OH to the reaction mixture. The clear light orangish brown solution was kept for
stirring for 24 hours at room temperature. The organic solution was washed with saturated
NaHCO3 (3 x 50 mL), 10% citric acid solution (3 x 40 mL) and brine (3 x 20 mL). The organic
solution was dried using anhydrous Na2SO4 and dichloromethane was removed using rotary
evaporation. The product was purified using column chromatography using ethyl acetate to yield
yellow oil (1.11 g, 69 %) ESI-HRMS: m/z calculated for C17H26N3O5, 352.1872; observed
1

[M+H]+ 352.1863, H NMR (400 MHz, CDCl3): δ 8.49 (dd, 3JH-H = 8.0 Hz, 4.0 Hz, 1H), 8.35 (d,
3

JH-H = 2.4 Hz, 1H), 7.48 (dt, 3JH-H = 8.0 Hz, 2.0 Hz, 1H), 7.22 (dd, 3JH-H = 8.0 Hz , 4.0 Hz, 1H),
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6.72 (d, NH of 3-Pal, 3JH-H = 4.0 Hz, 1H), 4.91 ( s, NH of Ala, 1H), 4.86 (m, α CH of 3-Pal, 1H),
4.12 (m, α CH of Ala1, 1H), 3.74 (s, 3H), 3.14 (m, CH2 of 3-Pal, 2H), 1.43 (s, 9H), 1.32 (d, CH3
of Ala, 3JH-H = 8.0 Hz, 3H)
2.11.2

Boc-Ala-Ala-3-Pal-OMe, 2.2

The tert-butoxycarbonyl group (Boc) was removed from Boc-Ala-3-Pal-OMe (2.1) using 50 %
trifluoroacetic acid in dichloromethane. The reaction mixture was stirred for one hour at room
temperature, following which the solvent was removed using rotary evaporation. The deprotected
peptide was coupled to another amino acid Boc-Ala-OH using the procedure mentioned for 2.1.
The product was purified using column chromatography using methanol-dichloromethane (06:94)
to afford a light yellow oil (0.66 g, 48%) ESI- HRMS: m/z calculated for C20H31N4O6, 423.2244;
1

observed [M+H]+ 423.2243, H NMR (400 MHz, CDCl3): δ 8.48 (dd, 3JH-H = 8.0 Hz, 4.8 Hz, 1H),
8.34 (d, 3JH-H = 4.0 Hz, 1H), 7.48 (dt, 3JH-H = 8.0 Hz, 4.0 Hz, 1H), 7.23 (m, 1H), 6.80 (s, 3JH-H = 4.0
Hz, NH of 3-Pal, 1H), 6.68 (d, 3JH-H = 6.0 Hz, NH of Ala 2, 1H ), 5.01 (bs, NH of Ala 1, 1H), 4.854.79 (m, α CH of 3-Pal, 1H), 4.40 (quint, 3JH-H = 16.0 Hz, 8.0 Hz, α CH of Ala 2, 1H), 4.12 (m, α
CH of Ala 1, 1H), 3.74 (s, 3H), 3.20 (m, CH2 of 3-Pal, 2H), 1.44 (s, 9H), 1.34 (d, CH3 of Ala 1
and 2, 3JH-H = 8.0 Hz, 6H)
2.11.3

Boc-Ala-Ala-Ala-3-Pal-OMe, 2.3

Deprotected peptide (2.2) was coupled to another amino acid Boc-Ala-OH using the same
procedure as 2.1. The crude product was purified by column chromatography using methanol and
ethyl acetate (1:9).This afforded an off white solid (0.53 g, 71%) ESI-HRMS: m/z calculated for
1

C23H36N5O7 494.2615; observed [M+H]+ 494.2654, H NMR (400 MHz, CDCl3): δ 8.45 (dd, 2JHH=

8.0 Hz, 3JH-H = 4.0 Hz, 1H), 8.42 (s, 1H), 7.55 (dt, 3JH-H = 8.0 Hz, 4.0 Hz, 1H), 7.20 (dd, 3JH-H

= 8.0 Hz, 4.0 Hz, 1H), 7.14 (d, NH of 3-Pal, 3JH-H = 8.0 Hz, 1H), 6.73 (d, 3JH-H = 8.0 Hz, 1H), 5.12
( s, NH of Ala, 1H), 4.83 (m, α CH of 3-Pal, 1H), 4.45 (quint, 3JH-H = 12.0 Hz, 8.0 Hz, α CH of
Ala 3, 1H), 4.40 (m, α CH of Ala 2, 1H), 4.12 (m, α CH of Ala 1, 1H), 3.73 (s, 3H), 3.14 (dd, 2JHH

= 16.0 Hz, 3JH-H = 2.4 Hz, βH of CH2 of 3-Pal, 2H), 3.13 (dd, 2JH-H = 16.0 Hz, 3JH-H = 2.4 Hz,

β’H of CH2 of 3-Pal 1H), 1.45 (s, 9H), 1.40 (d, 3JH-H = 8.0 Hz, 3H), 1.37 (d, CH3 of Ala, 3JH-H =
8.0 Hz, 3H), 1.33 (d, CH3 of Ala, 3JH-H = 8.0 Hz, 3H).
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2.11.4

Pyta-Ala-Ala-Ala-3-Pal-OMe, 2.4

Deprotected peptide (2.3) was coupled to the ligand pyridyl triazole acetic acid (pyta) using the
same procedure as 2.1. Purification was attempted using column chromatography using methanol
in dichloromethane (1:9) which afforded a minute amount of white solid (2 mg) ESI-HRMS: m/z
calculated for C27H34N9O6, 580.2632; observed [M+H]+ 580.2599
Peptide synthesis (Solid phase)
Peptide was synthesized from C to N terminus on a solid phase support with C terminus being
attached to the insoluble resin. Peptides were synthesized using standard solid phase peptide
synthesis technique and the linear peptide was synthesized using fluorenyl methyloxycarbonyl
(Fmoc) chemistry. The N terminal of each amino acid is Fmoc protected and the side chains are
acid labile. Rink amide MBHA resin (0.39 meq/g) was used as a solid support. The rink amide
resin was swollen in dimethyl formamide for 15 minutes. Each amino acid was Fmoc deprotected
using 20% piperidine in dimethyl formamide for two cycles (5 minutes and 15 minutes). Coupling
reactions were carried out with 3 eq. Fmoc protected amino acid, 3 eq. HCTU (2-(6-chloro-1Hbenzotriazole-1-yl)-1,1,3,3- tetramethyl ammonium hexafluorophosphate) and 6 eq. of DIPEA
(N,N- diisopropylethylamine). The coupling reaction was carried out for 60-90 minutes. The resin
beads were washed with excess dimethyl formamide and dichloromethane after each coupling and
deprotection cycles. The bidentate ligand (pyta and 2,2’-bipyridyl-4-carboxylic acid) were coupled
to the peptide with the (N,N,N’,N′-tetramethyl-O- (N-succinimidyl) uronium tetrafluoroborate)
TSTU and DIPEA in DMF, to prepare the pre-activated ester. The peptide was cleaved from the
resin using a cocktail mixture of 95% (v/v) trifluoroacetic acid (TFA), 2.5% (v/v) tri-isopropyl
silane (TIPS) and 2.5% (v/v) water for 5h. The cleaved peptide was precipitated with tert-butyl
methyl ether (TBME) and centrifuged at 3000 rpm for 10 minutes. After decanting, the peptide
was frozen and lyophilized to remove any remaining solvents. The peptide was purified with
reverse phase preparative HPLC, and the purity was checked by analytical UHPLC. Each of the
following peptides synthesized resulted in purity > 95%.
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Pyta-Ala-Ala-Ala-3Pal, 3.1

2.12.1

The linear peptide was synthesized using the general procedure for solid phase peptide synthesis
mentioned above (2.12). This afforded pure peptide in the form of white fluffy solid (0.017 g,
1

30%) H NMR (400 MHz, CDCl3): δ 8.67-8.62 (m, Ar-H + NH of Ala 3, 1H), 8.61-8.59 (m, 1H),
8.52 (s, 1H), 8.17 (d, 3JH-H = 8.0 Hz, 1H), 8.13 (d, 3JH-H = 8.0 Hz, 1H), 8.03 (dt, 3JH-H = 8.0 Hz, 1.2
Hz, 1H), 7.93-7.90 ( m, NH of 3Pal + Ar-H, 2H), 7.84 (d, 3JH-H = 4.0 Hz, NH of Ala1, 1H), 7.72
(dd, 3JH-H = 8.0 Hz, 5.2 Hz, 1H), 7.39 (s, 1H), 7.37-7.33 (m, 1H), 7.22 (s, 1H), 5.23 (s, 2H), 4.49
(m, α CH of 3Pal,1H), 4.34 (quint, 3JH-H = 12.0 Hz, 8.0 Hz, α CH of Ala 3, 1H), 4.22 (quint, 3JH-H
= 12.0 Hz, 8.0 Hz, α CH of Ala 2, 1H), 4.10 (quint, 3JH-H = 12.0 Hz, 8.0 Hz, α CH of Ala 1, 1H),
3.17 (dd, 2JH-H = 16.0 Hz, 3JH-H = 8.0 Hz, ß H of 3pal, 1H), 2.92 (dd, 2JH-H = 12.0 Hz, 3JH-H = 8.0
Hz, ß’ H of 3pal, 1H), 1.23 (d, 3JH-H = 4.0 Hz, CH3 of Ala 3, 3H), 1.16 (d, 3JH-H = 4.0 Hz, CH3 of
Ala 2, 3H), 1.07 (d, 3JH-H = 4.0 Hz, CH3 of Ala 1, 3H).
Optimization using temperature and time (general procedure)
Linear peptide pyta-Ala-Ala-Ala-3Pal (3.5 µmol, 1 eq) was dissolved in 2 mL of distilled water.
[Re(CO)3(OH2)3]OTf (3.2 µmol, 0.9 eq)was added to the reaction mixture. The clear reaction
mixture was stirred for 0 - 4 hours at four different temperatures 0º C, RT, 50º C, 100º C. Aliquots
(50µL) from the reaction mixture were taken after every 30 minutes and diluted with (100 µL) of
Milli Q water. The percentages are obtained by quantification done on the Waters, Inc. Acquity
UHPLC.
Optimization using change of solvent
Linear peptide pyta-Ala-Ala-Ala-3Pal (3.5 µmol, 1eq) was dissolved in 2 mL of methanol.
Re(CO)3(OH2)3OTf (3.2 µmol, 0.9 eq)was added to the reaction mixture. The clear reaction
mixture was stirred for 2 hours at 50º C. Aliquot (50µL) from the reaction mixture were taken at
2-hour time point and diluted with (100 µL) of Milli Q water and compared with the quantification
obtained from reaction using distilled water as a solvent. The percentages are obtained by
quantification done on the Waters, Inc. Acquity UHPLC
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Optimization by presence of base
Linear peptide pyta-Ala-Ala-Ala-3Pal (3.5 µmol, 1eq) was dissolved in 2 mL of distilled water.
Re(CO)3(OH2)3OTf (3.2 µmol, 0.9 eq)was added to the reaction mixture along with 5M
NaOH(17.5 µmol, 5eq) as a base. Reaction was performed at 50º C for 2 hours in presence of a
base. Aliquot (50 µL) from the reaction mixture were taken at 1-hour interval for the 2 hours
reaction and diluted with (100 µL) of Milli Q water and compared with the quantification obtained
from reaction carried out in absence of base. The percentages are obtained by quantification done
on the Waters, Inc. Acquity UHPLC.
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3 Chapter Three
3

Cyclization of small linear peptides by creating metal foldamers
using 99mTc/ Re(CO)3 core

Short linear peptides having 2-10 amino acids are quite flexible in solution and exist in a fast
equilibrium of interconverting conformations.1 For a biologically active peptide, out of these
conformations only a few have a suitable orientation for receptor binding. These short linear
peptides tend to lose their bioactive conformation due to their conformational flexibility causing
reduced specificity for the target. In addition, short linear peptides have reduced in vivo stability
due to degradation by proteolytic enzymes. These issues can be combated by various
peptidomimetic strategies, one of which is cyclization. Cyclization of these short linear peptides
can be envisioned to circumvent the problems by bringing rigidity to the linear structure, thereby
forming a limited number of conformations. This results in increased binding affinity and
improved stability by producing conformers that are insusceptible to proteolytic degradation.
Cyclization can be brought upon by various techniques like head to tail cyclization, side chain to
tail, side chain to side chain cyclization or by metal coordination. In this chapter, the focus is on
cyclization induced by metal coordination.
Metals are known to contribute towards the stabilization of protein macromolecular structure.2 The
scope of this chapter is focused on cyclization enabled by the group 7 transition metals rhenium
and technetium-99m. Cyclization of linear peptides using the radiometal
development of a possible SPECT imaging probe, as

99m

Tc would lead to

99m

Tc is known for its medical imaging

properties whereas rhenium, being an analogous group 7 metal, becomes the non-radioactive
counterpart. The design of rhenium/technetium‐containing diagnostic and therapeutic probes
allows the metals to be incorporated into the peptides by two methodologies: the traditional
pendant design or the integrated design. The pendant design is one of the most widely used
methods of attaching a metal to a peptide, by functionalization of a side chain lysine or a
carboxy/amine terminus through a bifunctional chelator. The bifunctional chelator coordinates the
metal from one end and is covalently attached to the peptide or targeting entity of interest from the
other end (figure 3.1-a). This design places the metal in a position far away from the biological
target, which may lead to decreased affinity of the original molecule for the target receptor.3 On
the other hand, the second methodology called the integrated design allows the metal complex to
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be incorporated directly into the structure of the biomolecule. This makes the labelling element a
critical component of the biologically active region. Integrated design allows cyclization where
the metal chelator is present either in the turn region of the peptide (figure 3.1-b) or a chelator is
formed at the terminal ends of the peptide through metal coordination (figure 3.1- c). This approach
hides the metal core within the ligand framework producing a more stable, compact, low molecular
weight chelation system.
a

b

c

Figure 3.1 a) Pendant design; b-c) Integrated designs
Metal complexes in the form of M(CO)3(H2O)3 (M= Re,

99m

Tc) are attractive organometallic

frameworks to be used for chelation with a peptide. This is due to the combined effect of high
substitution stability of the CO ligands and lability of water molecules. This allows the substitution
of water molecules with different types of monodentate, bidentate and tridentate ligands of
different shape, size and different donor atoms.4 Tridentate chelates have faster clearance and are
more stable to substitution in comparison to bidentate [99mTc(CO)3]+ complexes. However, a
bidentate ligand when accompanied by a monodentate ligand shows improved stability and gives
rise to a mixed ligand system. This type of mixed ligand system is called a 2+1 chelation system.
The 2+1 mixed ligand chelation approach has an advantage of flexibility in structural
modifications, high in vivo stability and an increased yield of metal complex even at low ligand
concentrations (10-5 M). The monodentate ligands can be phosphines (P), isocyanides (CNR) or
aromatic amines. The bidentate ligand can be of various donor types which includes (N,O) donors
such as 2-picolinic acid,5 (S,S) donors, such as dithiocarbamate,6 (P,P) donors, such as biphosphine
ligands7 and (N,N) donors, such as bipyridine 8 (Figure 3.2).
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a

b

c

d

Figure 3.2 Mixed ligand systems having a) N, O bidentate donors; b) O, O donors; c) S, S
donors; d) N, N donors.
In recent years, there has been a significant increase in the use of pyridine base ligands as chelators
for the M(CO)3+ core. Several common examples include 2,2’-bipyridine,9 picolinic acid,10 DPA11
and asymmetrical pyridine base ligands.7,12,13 Bipyridine has been a widely studied bidentate
ligand for metal coordination. It forms a very stable five membered chelate ring with transition
metals. Several studies have reported use of bipyridine as a chelator for coordination with rhenium
tricarbonyl core.14,15 Yazdani et.al demonstrated the use of 2,2’-bipyridine and imidazole base
donors for rhenium tricarbonyl coordination, which led to the development of redox probes and
luminescent labels for biomolecules (Figure 3.2-d). The advantage of this 2 + 1 chelation system
was the exhibition of broad excitation (350-410 nm) and emission bands (500-700 nm) along with
large stokes shift and long lifetimes where an appropriate vector, when attached to either bidentate
or monodentate ligand, could lead to the targeting of specific cellular compartments.8
In addition to 2,2’- bipyridine, 4-(2-pyridyl)-1,2,3-triazole (pyta) derivatives have garnered
increasing attention. This is mainly due to the potent ability of the triazoles to coordinate with
various transition metals.16 A study by Connell et.al focused on use of a pyta derivative to
coordinate the facial rhenium tricarbonyl core (figure 3.3-a). The ligand was elaborated with a
terminal isothiocyanate functional group through both an aromatic and polyethylene glycol spacer.
A targeting peptide, arginine–glycine–aspartate (RGD), was conjugated to pyridyl-1,2,3-triazole
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bidentate ligands via the isothiocyanate functional group (Figure 3.3-b). The rhenium metal
complex of the following compound demonstrated phosphorescence properties which were used
in tracking the cellular metabolism and binding affinity of new complexes towards αvβ3 receptor
using confocal microscopy.17

a

b

Figure 3.3 a) Rhenium metal complex of isothiocyanate functionalized 4-(2-pyridyl)-1,2,3 triazole
and pyridine ligand; b) cyclic cRGDfK conjugate of isothiocyanate functionalized 4-(2-pyridyl)1,2,3 triazole ligand.
Using this ideology, our project aims to use the bidentate ligands 2,2’-bipyridine and pyridyl
triazole along with monodentate pyridine base ligand to cyclize linear peptides in 2+1 chelation
fashion. The linear peptides used for the study are the tri-alanine sequence Ala-Ala-Ala and the
biologically relevant peptide Arg-Gly-Asp (RGD). The peptide sequence RGD was chosen as it is
known to have affinity for αvβ3 which is often overexpressed at tumor sites, including prostate,
breast, ovarian, cervical, pancreatic, melanoma, and glioblastoma tumors, whereas the Ala-AlaAla peptide sequence is chosen due to its higher propensity to form a helical structure.18 The model
peptide would be studied to demonstrate a turn induced with the aid of the M(CO)3 core (where
M= Re, 99mTc). Following the study of model tri-alanine peptide sequence, we aim to use M(CO)3
core to cyclize the biologically relevant peptide sequence RGD and study the effect of cyclization
through NMR spectroscopy and mass spectrometry.

Results and Discussion
To investigate the ability of

99m

Tc/Re tricarbonyl to induce a turn in the linear peptide, we
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synthesized linear peptides of sequence Ala-Ala-Ala and the biologically relevant peptide
sequence RGD using solid phase peptide synthesis. In addition to pyridyl triazole acetic acid
(pyta), a different bidentate ligand, 2,2’- bipyridine-4-carboxylic acid, was synthesized in order to
study its ability to coordinate the metal tricarbonyl core. 2,2’-Bipyridine-4-carboxylic acid (Bipyd)
was synthesized as shown in the Scheme 3.1.19

Scheme 3.1 Synthesis of 2,2’-bipyridine-4-carboxylic acid19, 8
Linear peptide sequences pyta-Ala-Ala-Ala-3Pal, pyta-RGD-3Pal, Bipyd-Ala-Ala-Ala-3Pal and
Bipyd-RGD-3Pal were synthesized and characterized by NMR spectroscopy and mass
spectrometry. The NMR spectroscopy results of the linear peptides would then be used to
compare the changes in chemical shifts for amino acids observed on cyclization using the metal
tricarbonyl core.
3.1.1

Synthesis of linear peptide

The linear sequences were synthesized by standard Fmoc solid phase peptide synthesis method.
Rink amide resin (MBHA) was used as a solid support and the peptide was synthesized from C to
N terminus. Each amino acid already had a Fmoc protecting group along with side chains having
acid labile protecting groups. After the removal of the Fmoc, amino acid was vortexed with the
coupling agent, base in DMF prior to coupling with another amino acid. The N-terminus was
coupled with the ligand pyridyl triazole (pyta) and 2,2’- bipyridine-4-carboxylic acid (Bipyd)
respectively. Removal of all protecting groups and cleaving of the resin was performed using
cleavage cocktail (Scheme 3.2). The peptide was precipitated with cold tert-butyl methyl ether
(TBME), centrifuged, filtered and lyophilized to give crude linear peptide of the desired sequence.
The crude linear peptide was then purified by RP-HPLC to give a purity of > 95%
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Scheme 3.2 Synthesis of linear peptide sequences 3.1, 3.2, 3.6, 3.7 using Fmoc strategy

3.1.1.1

Cyclization of peptide sequence pyta-Ala-Ala-Ala-3Pal using
[Re(CO)3(OH2)3]+, 3.8

The linear peptide pyta-Ala-Ala-Ala-3Pal, (3.1) was coordinated to the rhenium tricarbonyl triaqua
[Re(CO)3(H2O)3]OTf complex where the [Re(CO)3(H2O)3]OTf

complex was synthesized

following the method reported by Schmidt et.al, by using commercially available
bromopentacarbonyl rhenium (I), Re(CO)5Br.20 The coordination was done in distilled water at
50°C for 2 hours (Scheme 3.3).

43

Ala 3

Ala 2

Ala 2

H2O, 50° C, 2h

Ala 1

Ala 3

3.1

3.8

Ala 1

Scheme 3.3 Rhenium coordination of linear peptide pyta-Ala-Ala-Ala-3Pal, 3.1
Upon coordination, three conformers for rhenium coordinated product were observed. The reaction
conditions allowed the formation of one conformer in higher yield in comparison to the other two
conformers (Figure 3.4). RP-preparative HPLC did not allow complete separation of the two later
eluting conformers due to their proximity to each other, however, the dominant conformer was
separated. While, all three conformers show identical product m/z values, it remains possible that

Absorbance (AU)

the later eluting products are dimers. However, this requires additional investigation.

Dominant
conformer, A

Less dominant conformer/isomer, (B, C)

Figure 3.4 UHPLC chromatogram of the cyclic peptide Re(CO)3[Pyta-Ala-Ala-Ala-3Pal], 3.8
Acetonitrile is a remarkable coordinating solvent and in acidic conditions it appears that some of
monodentate chelator was replaced by the solvent while passing through the HPLC column. It was
observed during the purification of the cyclic peptide using HPLC, acetonitrile adducts of the
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cyclic peptide were formed. In contrast, no such issues were encountered when acetonitrile was
replaced with methanol as an eluent. Thus, to avoid the formation of the acetonitrile adducts, an
eluent system of methanol-water was used for the HPLC purification of the cyclic peptide leading
to the isolation of the predominant cyclic peptide with a purity of 96.5%.

NMR spectroscopic studies of the linear peptide, 3.1 and cyclic peptide, 3.8
The linear and cyclic peptides were characterized using 1H NMR spectroscopy. An overlapping of
peaks is seen in the aromatic region of the linear peptide. However, it is observed that cyclization
of the linear peptide led to the separation of the peaks. Figure 3.5 shows the aromatic region from
the NMR spectra for both the linear and cyclic peptide.

Figure 3.5 Aromatic region from 1H NMR spectra of cyclic (3.8) and linear peptide (3.1)

2D- NMR spectroscopic characterization of cyclic peptide, 3.8
For identification of the individual amino acids, we characterized the linear and cyclic peptides
using COSY and NOESY NMR spectroscopy. Shown below is the COSY NMR spectra for the
cyclic peptide 3.8 (Figure 3.6). COSY NMR spectra was used by us to observe the correlation of
the CH3 protons peaks to the neighboring α CH proton and then to the respective NH proton. This
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led to the identification of the individual CH3, NH and α CH protons of each amino acid in the
peptide sequence.
COSY NMR spectra

Figure 3.6 COSY NMR spectra of cyclic peptide 3.8, in DMSO-d6 at 400 MHz
In order to identify the position of each amino acid in the peptide sequence, we characterized the
cyclic peptide, 3.8 using NOESY NMR spectroscopy. Correlation between amide NH protons and
α CH protons of the spatially adjacent amino acids was observed. Using this information, we
identified the position of individual amino acids in the peptide sequence and were able to illustrate
the structure of the cyclic peptide, 3.8 (Figure 3.7). All the synthesized linear and cyclic peptides
were characterized by 1H, 2D COSY and NOESY NMR spectroscopy in a similar manner.
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NOESY NMR spectra
Ala 3
Ala 2
Ala 1
α CH of Ala 1 - NH of 3Pal
α CH of Ala 3 - NH of Ala 2
α CH of Ala 2 - NH of Ala 1
Pyta CH2 - NH of Ala 3

Figure 3.7 NOESY NMR spectra of cyclic peptide 3.8, in DMSO-d6 at 400 MHz
The slight change in chemical shift before and after cyclization of the peptide is shown in the
table 3.1
Table 3.1 Amino acids proton shifts (ppm) of the linear peptide Pyta-AAA-3-Pal-NH2, 3.1 and
rhenium coordinated peptide, 3.8
Pyta-Ala-Ala-Ala-3Pal

Re(CO)3Pyta-Ala-Ala-Ala-3Pal

Amino acid

CH3

α CH

NH

CH3

α CH

NH

Alanine 1

1.07

4.10

7.84

1.10

4.12

7.86

Alanine 2

1.16

4.22

8.17

1.19

4.25

8.24

Alanine 3

1.23

4.34

8.67

1.26

4.36

8.86

3-Pal

3.05, 3.03

4.49

7.93

3.06, 3.04

4.46

7.92
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A downfield shift was seen for the amide protons of the three alanine, on comparing the chemical
shifts between linear and cyclic peptide. However, a slight upfield shift for amide proton of 3-Pal
was observed. Cyclization of the linear peptide deshielded the methyl protons of all three alanine,
which can be observed from the difference in their chemical shift. Methylene protons of 3-Pal
showed a slight upfield shift on cyclization. All α CH protons show a downfield shift except the
α CH proton of 3-pyridyl alanine, where an upfield shift is observed. The α CH protons of 3pyridiyl alanine shows up field shift which may be due to its close proximity to the metal. This
proves that 3-Pal is coordinated to metal in monodentate fashion. The distereotopic protons of pyta
were equivalent in the linear form of the peptide and had a singlet pattern. However, these protons
no longer showcase a singlet pattern on cyclization. This might be due to the restriction in
flexibility induced by the metal upon cyclization which makes the two protons non-equivalent.
This shows that the ligand has coordinated the metal in a bidentate fashion

3.1.1.2

Cyclization of peptide sequence pyta-RGD-3Pal using
[Re(CO)3(OH2)3]+, 3.9

The linear peptide pyta-Arg-Gly-Asp-3Pal was coordinated to the rhenium tricarbonyl triaqua
[Re(CO)3(H2O)3]OTf complex in a similar method as mentioned for 3.8 (Scheme 3.4). Upon
analysis by LCMS, three conformers of the cyclic peptide were seen. Purification was done using
reverse phase HPLC and the cyclic products were isolated with a collective purity of >99% for
the coordinated peptides.

H2O, 50° C, 2h

Scheme 3.4 Rhenium coordination of linear peptide pyta-RGD-3Pal, 3.2
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Table 3.2 Chemical shifts for the amino acids in the linear 3.2, and cyclic peptide Pyta-RGD3Pal, 3.9
Amino acid

Pyta-RGD-3Pal

Re(CO)3Pyta-RGD-3Pal

βCH2

α CH

NH

βCH2

α CH

NH

Arginine

1.75, 1.62

4.40

8.72

1.75, 1.63

4.40

8.88

Glycine

-

3.74

8.42

-

3.74

8.45

Aspartic acid

2.62, 2.42

4.49

8.22

2.62, 2.42

4.52

8.22

3-Pal

3.20, 2.94

4.47

8.07

3.20, 2.95

4.47

8.07

It is interesting to see that the on cyclization, only the amide protons of for arginine and glycine
show downfield shifts whereas there is no change seen for aspartic acid and 3-Pal. Similar to 3.8,
separation of the peaks can be seen once the linear peptide is coordinated.

3.1.1.3

Cyclization of peptide sequence Bipyd-Ala-Ala-Ala-3Pal using
[Re(CO)3(OH2)3]+, 3.13

The conditions for coordinating the linear peptide Bipyd-Ala-Ala-Ala-3Pal with rhenium
tricarbonyl triaqua [Re(CO)3(H2O)3]OTf complex were kept similar except for the slight change
in time and temperature (Scheme 3.5). The reaction was extended, with stirring for 4 hours at 60°
C. Upon analysis by LCMS, two conformers of the cyclic peptide were seen. Purification was done
using reverse phase HPLC and the cyclic products were isolated with a collective purity of > 99%
for the coordinated peptides
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H2O, 50° C, 2h

Scheme 3.5 Rhenium coordination of linear peptide Bipyd-Ala-Ala-Ala-3Pal, 3.6
Table 3.3 Chemical shifts for the amino acids in the linear 3.6, and cyclic peptide Bipyd-AlaAla-Ala-3Pal, 3.13
Amino acid

Bipyd-Ala-Ala-Ala-3Pal

Re(CO)3Bipyd-Ala-Ala-Ala-3Pal

CH3

α CH

NH

CH3

α CH

NH

Alanine 1

1.14

4.13

7.88

1.14

4.15

7.89

Alanine 2

1.20

4.26

8.16

1.21

4.27

8.27

Alanine 3

1.37

4.49

9.06

1.39

4.56

9.24

3.10, 3.09

4.53

7.96

3.04, 3.05

4.49

7.94

3-Pal

Similar to 3.8, there was a downfield shift observed for the α CH protons for all the amino acids
except for the 3-pyridyl alanine. 3-Pal being close to the rhenium metal core shows an upfield shift
which proves the hypothesis that it is coordinating the metal in monodentate fashion. It is quite
interesting to observe that the amide protons for all the amino acids except 3-Pal show downfield
shift upon cyclization.
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3.1.1.4

Cyclization of peptide sequence Bipyd-Arg-Gly-Asp-3Pal using
[Re(CO)3(OH2)3]+, 3.14

The linear peptide Bipyd-Arg-Gly-Asp-3Pal was coordinated to the rhenium tricarbonyl triaqua
[Re(CO)3(H2O)3]OTf complex in a similar method as mentioned for 3.13 (Scheme 3.6). Upon
analysis by LCMS, two conformers of the cyclic peptide were seen. Purification was done using
reverse phase HPLC and the cyclic products were isolated with a collective purity of >99% for the
coordinated peptides Characterization using

1

H NMR, 2D g-COSY and NOESY NMR

spectroscopy gave results mentioned in the table 3.4.

H2O, 50° C, 2h

Scheme 3.6 Rhenium coordination of linear peptide Bipyd-RGD-3Pal, 3.7
Table 3.4 Chemical shifts for the amino acids in the linear 3.7, and cyclic peptide Bipyd-RGD3Pal, 3.14
Amino acid

Re(CO)3Bipyd-RGD-3Pal

Bipyd-RGD-3Pal
βCH2

α CH

NH

βCH2

α CH

NH

Arginine

1.83, 1.77

4.56

9.11

1.81-1.71

4.59

9.32

Glycine

-

3.74

8.40

-

3.76

8.51

Aspartic acid

2.65, 2.44

4.51

8.10

2.65, 2.45

4.52

8.18

3-Pal

3.21, 2.95

4.48

8.10

3.15, 2.91

4.44

8.05
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Interesting observations were made on comparing the NMR spectra of the linear and cyclic
peptide. A downfield shift is observed in the chemical shift of amide protons for all the amino
acids except for 3-Pal. A similar trend is also seen in the chemical shifts of the α CH proton where,
except for 3-Pal, the other amino acids show a slight downfield shift.

Optimization of peptide sequence length
It was observed that despite of carrying out the coordination reaction at conditions to give an
optimal yield, not all of the linear peptide was converted into cyclic peptide. The length of the
linear peptide might be affecting its flexibility in creating a turn around the metal core. In order to
study the effect of the peptide length on the coordination reaction, we synthesized a series of model
peptides with increasing peptide length. The peptide sequences synthesized were pyta-Ala-AlaAla-Ala-3Pal, pyta-Ala-Ala-Ala-Ala-Ala-3Pal with an increased length to 6 and 7 amino acids
respectively. Another chosen peptide sequence was pyta-Ala-ala-Ala-3Pal where the amino acid
in the center is a D-amino acid instead of the natural L-amino acid. D- amino acids are known to
aid in cyclization by conformational preorganization. All of the three peptides were coordinated
to the rhenium tricarbonyl core (Scheme 3.7) and were quantified by analytical UHPLC.
It was assumed that as the length of the peptide would increase, the ease of cyclization would give
an increased yield of cyclic product. However, as the number of alanine amino acid increased in
the linear sequence, the solubility of the peptide in water was affected. This is due to hydrophobic
nature of the methyl group present as a side chain on alanine. Out of the three peptides synthesized,
only pyta-Ala-Ala-Ala-Ala-3Pal gave a considerable yield on cyclization. Thus, pyta-Ala-AlaAla-Ala-3Pal was used for further studies along with the pentapeptide sequences.
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H2O, 50° C, 2h

3.3
3.10

H2O, 50° C, 2h

3.4
3.11

H2O, 50° C, 2h

3.5

3.12

Scheme 3.7 Cyclization reaction of linear peptide sequences with varying length, (3.3 - 3.5)

Variable temperature NMR studies
VT NMR spectroscopy is one of the most common methods used for studying intramolecular
hydrogen bonds.21 There is a strong dependence of the amide protons chemical shift on
temperature. Increasing temperature causes an upfield shift in amide protons; however, if the
proton is hydrogen bonded, the shift is considerably less. The chemical shifts of amide protons
involved in intramolecular hydrogen bonding will not be as sensitive to changes in temperature in
contrast to those that are not hydrogen bonded or are intermolecularly hydrogen bonded to the
surrounding solvent. This can be tracked quantitatively by dividing the change in shift over the
change in temperature (Δδ/ΔT). Δδ/ΔT values that are more positive than -4.6 ppbK-1 correspond
to protons that are involved in intramolecular hydrogen bonding22. Thus, the amide peaks were
assigned to individual amino acids using g-COSY and NOESY NMR spectroscopy. These peaks
were then observed at increasing temperature to determine which of them displays intramolecular
hydrogen bonding.
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-Ala 3

NH-Ala 2

NH-Ala 1

Figure 3.8 VT 1H NMR spectra of coordinated peptide 3.8 in DMSO-d6 at 5°C intervals from 2560° C at 600 MHz
VT NMR spectroscopy studies were performed on the coordinated peptides in dimethylsulfoxided6 (DMSO-d6) from 25-60°C at 5° C intervals. As the temperature increases, a difference in the
magnitude of the change in shift can be seen for each individual proton. When the chemical shifts
were converted to numerical values, all the amide bonds except 3-Pal were present in the range of
0 ≥ Δδ/ΔT ≥ - 4.6 ppbK-1, indicating that hydrogen bonding exists within the peptide backbone. 3Pal showing the value of -4.85 ppbK-1 might not be involved in hydrogen bonding. Figure 3.8
shows the superimposed series of 1H NMR spectra for 3.8, obtained at increasing temperature.
Table 3.5 The Δδ/ΔT values obtained from the VT 1H NMR spectra analysis for each amide
proton in peptide 3.8
Δδ/ΔT (ppb/K)
Ala 1 NH

Ala 2 NH

Ala 3 NH

3-Pal NH

- 3.71

- 4.28

- 3.71

- 4.85
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Re(CO)3[Pyta-RGD-3Pal], (3.9)
Variable temperature interpretations were done for peptide Re(CO)3[Pyta-RGD-3Pal] in a similar
manner to 3.8. The values from VT 1H NMR spectra suggest that except 3-Pal, all the other three
amino acids are involved in intramolecular hydrogen bonding.
Table 3.6 The Δδ/ΔT values obtained from the VT 1H NMR spectra analysis for each amide
proton in peptide 3.9
Δδ/ΔT (ppb/K)
Arg NH

Gly NH

Asp NH

3-pal NH

-3.71

- 4.28

-3.14

-6.0

Re(CO)3[Pyta-AAAA-3Pal], 3.10
Variable temperature interpretations were done for peptide Re(CO)3[Pyta-AAAA-3Pal] in a
similar manner to 3.8 and are presented in the table 3.7. The values from VT NMR spectra suggest
that all the amino acids are involved in intramolecular hydrogen bonding. Due to the presence of
the amide bonds of Ala 1, Ala 2 and 3-Pal as one multiplet, it was difficult to interpret the chemical
shifts individually.
Table 3.7 The Δδ/ΔT values obtained from the VT 1H NMR spectra analysis for each amide
proton in peptide 3.10
Δδ/ΔT (ppb/K)
Ala 1/ Ala 2 / 3-pal NH

Ala 3 NH

Ala 4 NH

-3.71

- 4.28

-3.4
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Re(CO)3[Bipyd-AAA-3Pal], 3.13
The values from VT NMR suggest that all the amino acids except 3-pyridyl alanine, are involved
in intramolecular hydrogen bonding. Figure 3.9 shows the superimposed series of 1H NMR spectra
obtained at increasing temperature.

Figure 3.9 VT 1H NMR spectra of coordinated peptide 3.13 in DMSO-d6 at 5°C intervals from
25-60°C at 600 MHz
Table 3.8 The Δδ/ΔT values obtained from the VT 1H NMR analysis for each amide proton in
peptide 3.13
Δδ/ΔT (ppb/K)
A1 NH

A2 NH

A3 NH

3-Pal NH

-3.14

- 4.28

-3.71

-4.85
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Re(CO)3[Bipyd-RGD-3Pal], 3.14
The values from VT NMR suggest that all the amino acids except for 3-pyridyl alanine, are
involved in intramolecular hydrogen bonding. The interpretations from the variable temperature
NMR are presented in the tabular form (Table 3.9).
Table 3.9 The Δδ/ΔT values obtained from the VT 1H NMR analysis for each amide proton in
peptide 3.14
Δδ/ΔT (ppb/K)
Arg NH

Gly NH

Asp NH

3-Pal NH

-3.14

- 2.00

-3.14

-5.71

Circular Dichroism Spectroscopy
Circular dichroism (CD) is a chiroptical method used to analyze chiral molecules like peptides,
proteins, nucleic acids, oligo- and polysaccharides. It is a widely used technique to determine the
secondary structure and can differentiate between a random coil (linear peptide) and an ordered
structure (cyclic peptide).23,24 All the linear and cyclic peptides were analyzed by CD spectroscopy.
The figure 3.8 presents the graphs of mean residue ellipticity vs wavelength for all the linear and
cyclic peptides.
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Wavelength

Wavelength

Wavelength

Wavelength

Wavelength

Figure 3.10 CD spectroscopy for the linear (3.1, 3.2, 3.3, 3.6, 3.7) and cyclic peptides, (3.8,
3.9, 3.10, 3.13, 3.14) in MilliQ water at a concentration of 0.25 mg/mL
It is quite interesting to see a change in conformation taking place when the peptide is coordinated
to the metal core using the ligand pyridyl triazole acetic acid (pyta). However, the same sequences
used with another ligand 2,2’-bipyridine-4-carboxylic acid do not show much change in
conformation. The linear peptides (random coil) show a strong minima at 200 nm, a characteristic
signal for a random coil, whereas alpha-helical structures usually show two minima at 208 and 222
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nm.25 The cyclic peptide sequence 3.8 shows a two minima at 202 nm and 220 nm along with a
maxima at 212 nm and 250 nm. A similar change in conformation is also seen for peptide 3.9,
where the graph shows the presence of two minima at 205 nm and 235 nm along with two maxima
at 220 and 260 nm. Peptide 3.10 shows similar minima at 200 and 235 nm along with one maxima
at 215 nm. Significant difference seen in the conformation suggests that a turn is induced by the
metal upon cyclization of the linear peptide and that peptides 3.8, 3.9, 3.10 appear to resemble that
of a helical peptide structure.

Tc labelling of linear peptide pyta-Ala-Ala-Ala-3pal

99m

The linear peptide, pyta-AAA-3Pal-NH2, was labelled with technetium-99m to provide 99mTc
coordinated peptide, [99mTc(CO)3(pyta-AAA-3Pal-NH2)] (Scheme 3.8). The pertechnetate was
added to the isolink kit following the microwave reaction conditions reported by Pitchumony et
al. which resulted in [99mTc(CO)3(OH2)3]+.9

60° C, 30 min

Scheme 3.8 99mTc labelling of Pyta-AAA-3Pal, 3.15
The reduced 99mTc was reacted with the linear peptide, producing the radiolabelled peptide. Both
technetium and rhenium belong to group 7 and thus it is assumed that they will behave in a similar
chemical manner. However, it was quite unique to observe that instead of forming the dominant
cyclic product that was observed in the case of rhenium cyclized peptide,

99m

Tc(CO)3+ did not

form the same cyclic product. A peak was expected at retention time of 7.80 mins, but on
technetium labelling two peaks at 9.80 and 10.23 mins were observed. These retention times
correlated with the retention times of the less dominant conformer/isomer cyclic product obtained
during rhenium coordination. These radiolabelled conformers were then purified with a Waters
Sep-Pak C18 Plus Cartridge. To demonstrate that the linear peptide was coordinated through
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99m

Tc(CO)3+, the crude radiolabelled peptide (A) was compared with the Re(CO)3+ coordinated

peptide (B) showing less dominant isomers and the purified dominant peak of Re(CO)3+
coordinated peptide (C) by analytical HPLC. The retention time of the conformer/ isomer of the
crude radiolabelled peptide in the gamma trace correlated with the less dominant conformer/isomer
peaks in the Re(CO)3+ coordinated peptide in the UV trace, Figure 3.11

A

B

C

Figure 3.11 Analytical HPLC traces showing correlations between γ trace of crude 99mTc(CO)3+
labelled peptide (A), 3.15 and UV trace of Re(CO)3+ coordinated peptide, 3.8 (B) showing less
dominant isomers and no correlation with UV trace of dominant peak of 3.8 (C).

Conclusion
A series of linear peptides were cyclized by bidentate coordination through two nitrogen atoms on
the pyridyl-triazole, and mono-dentate coordination from the nitrogen atom on the pyridine,
forming a 2+1 chelation system. This was studied by 1H NMR spectroscopy of linear and
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coordinated peptides, which showed considerable changes in chemical shifts upon cyclization.
Circular dichroism (CD) spectroscopy suggested formation of secondary structure upon metal
coordination as a change in conformation was seen. The peptides with pyta as the bidentate ligand
showed conformation usually seen for helical structures whereas the peptides with 2,2’-bipyridine4-carboxylic acid showed no significant change. Variable temperature (VT) NMR spectroscopy
was used to study the hydrogen bonding where selected amino acids showed intra-molecular
hydrogen bonding. Radiolabelling of the linear peptide with 99mTc(CO)3+, resulted in the formation
of conformers which were not dominant during Re(CO)3+coordination. However, there was a
corelation observed between the radiolabelled peak and two of the conformers formed during
rhenium coordination. We successfully demonstrated cyclization of linear pentapeptide sequences
using 99mTc/Re(CO)3+coordination by 2+1 chelation fashion.

Experimental data
All the reagents and solvents were purchased from Sigma Aldrich, Fischer Scientific, Alfa-Aesar,
Chem-Impex, Novabiochem, Oakwood Chemicals, Peptides International. For analytical UHPLCMS, studies were performed on a Waters, Inc. Acquity UHPLC system combined with Xevo QToF
mass spectrometer (ESI+, cone voltage = 30V). A Waters, Inc. Acquity UHPLC BEH C18 2.1 x
50 mm, 1.7 um column was used with a gradient solvent system consisting of 0.1% formic acid in
acetonitrile and 0.1% formic acid in water. Analysis of the peptides was carried out using a
reversed-phase analytical HPLC column (Agilent Zorbax SB-C18 column 4.6 x 150 mm, 3.5 µm).
The mobile phases employed were 0.1% TFA in water (solvent A) and 0.1% TFA in acetonitrile
(solvent B) and 0.1% TFA in methanol (solvent C) with a flow rate of 1.5 ml/min over 15 minutes.
The absorbance was monitored using a Waters 2998 Photodiode array detector set at 220 nm, 254
nm, and 400 nm. All peptides were purified using a reversed-phase preparative HPLC column
(Agilent Zorbax SB-C18 column 21.2 x 150 mm, 5 µm) with all system specifics being the same
as those used for the analytical system. The flowrate for the preparative HPLC was set at 20
mL/min. The collected fractions were then lyophilized to a solid, and subsequently analysed by
ESI-MS on a Acquity UHPLC-MS system (Waters Co.). The NMR spectroscopy experiments
were performed using Bruker Avance III HD 400 (B400) in deuterated dimethyl sulfoxide
o

(DMSO- d6) or CDCl3 at 25 C. Varian INOVA 600 NMR spectrometer was used for 1H, g-COSY
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and NOESY NMR spectroscopy studies. Chemical shifts are reported in parts per million (ppm)
relative to TMS (0.00 ppm).
3.7.1

Small molecule synthesis

3.7.2

4-methyl-2-bromo pyridine carboxylate, 6

2-Bromopyridine-4-carboxylic acid (0.01 mol, 2.02 g) was added to a round bottom flask
containing 40 mL of methanol. A few drops of concentrated sulfuric acid were added to the
solution and the reaction mixture was brought to reflux for 5-6 hours. Methanol was removed from
the clear solution using rotary evaporation. The product was diluted with distilled water and
transferred to a separatory funnel. Extraction of the organic product was done using chloroform
followed by washings with 20 % solution of sodium bicarbonate. The organic layer was dried and
concentrated to afford a pale yellowish white solid. ESI-LCMS: m/z calculated for C7H7BrNO2,
217.9917, observed, 217.9817 (1.5 g, 69 %) 1H NMR (400 MHz, CDCl3): δ 8.53 (d, J = 4.0 Hz,
1H), 8.04 (s, 1H), 7.80 (d, J = 4.0 Hz, 1H), 3.97 (s, 3H).
3.7.3

4-Methyl-2,2’-bipyridine carboxylate, 7

4-Methyl-2-bromo pyridine carboxylate, (6) (0.9 g, 4.16 mmol) was dissolved in a microwave vial
containing 10 mL of dry toluene, followed by addition of 2-(tri-n-butylstannyl) pyridine (1.574 g,
4.27 mmol). The resulting clear solution was degassed for 10 minutes followed by the addition of
tetrakis(triphenylphosphine)palladium (0.120 mg, 2.5 mol%). The yellow-coloured transparent
solution was allowed to stir in refluxing conditions at 110° C for 2 days. Potassium fluoride (0.288
g, 1.189 mmol dissolved in distilled water) was added and the reaction mixture was allowed to stir
for 30 minutes at room temperature. A blackish grey precipitate was filtered off from the reaction
mixture followed by extraction of the organic product using toluene (3 x 40 mL). The organic
layers were combined, dried and concentrated. Column chromatography was used to purify the
crude product using ethyl acetate: hexanes (1:4) which afforded a white solid. Characterization
was identical to published values19 (0.892 g, 40 %) ESI-HRMS: m/z calculated for C12H11N2O2,
215.0821, observed, 215.0812, 1H NMR (400 MHz, CDCl3): δ 8.94 (m, 1H), 8.83 (d, 3JH-H = 4.0
Hz, 1H), 8.73 (m, 1H), 8.42 (d, 3JH-H = 8.0 Hz, 1H), 7.88-7.82 (m, 2H), 7.35 (dd, 3JH-H = 8.0 Hz,
4.0 Hz, 1H), 3.98 (s, 3H). 13C{1H} NMR (400 MHz, CDCl3): δ 165.7, 157.3, 155.1, 149.9, 149.4,
138.5, 137.0, 124.1, 122.7, 121.3, 120.3, 52.6.
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3.7.4

2,2’-bipyridine carboxylic acid, 8

4-Methyl-2,2’-bipyridine carboxylate, 7 (0.360 g, 1.68 mmol) was dissolved in 10 mL of methanol
in a round bottom flask. To it was added 10 % KOH aqueous solution (2-3 mL). The reaction
mixture was kept for stirring at room temperature for 3 hours. The resulting clear solution was
concentrated, and the product was precipitated out of the solution using 1M HCl which afforded a
white colored solid (0.28 g, 84 %), ESI-HRMS: m/z calculated for C11H9N2O2, 201.0664,
observed, 201.0647; 1H NMR (400 MHz, DMSO): δ 13.78 (bs, 1H), 8.87 (dd, 3JH-H = 4.0 Hz, 1.7
Hz, 1H), 8.83 (m, 1H), 8.73 (m, 1H), 8.41 (m, 1H), 7.98 (td, 3JH-H = 8.0 Hz, 1.8 Hz 1H), 7.87 (dd,
3

JH-H = 4.0 Hz, 1.7 Hz, 1H), 7.50 (m, 1H).

13

C{1H} NMR (400 MHz, DMSO): δ 166.6, 156.6,

154.7, 150.8, 150.1, 140.1, 138.2, 125.3, 123.3, 121.1, 120.21.
3.7.5

Peptide synthesis

Peptide was synthesized from C to N terminus on a solid phase support with C terminus being attached
to the insoluble resin. Peptides were synthesized using standard solid phase peptide synthesis technique
and the linear peptide was synthesized using fluorenylmethyloxycarbonyl (Fmoc) chemistry. The N
terminal of each amino acid is Fmoc protected and the side chains are acid labile. Rink amide MBHA
resin (0.39 meq/g) was used as a solid support. The rink amide resin was swollen in dimethyl
formamide for 15 minutes. Each amino acid was Fmoc deprotected using 20% piperidine in dimethyl
formamide for two cycles (5 minutes and 15 minutes). Coupling reactions were carried out with 3 eq.
Fmoc protected amino acid, 3 eq. HCTU(2-(6-chloro-1H-benzotriazole-1-yl)-1,1,3,3- tetramethyl
ammonium hexafluorophosphate) and 6 eq. of DIPEA (N, N- diisopropylethylamine). The coupling
reaction was carried out for 60-90 minutes. The resin beads were washed with excess dimethyl
formamide and dichloromethane after each coupling and deprotection cycles. The bidentate ligand
(pyta and 2,2’-bipyridyl-4-carboxylic acid) were coupled to the peptide with the (N,N,N′,N′tetramethyl-O- (N-succinimidyl) uronium tetrafluoroborate) TSTU and DIPEA in DMF, to prepare the
pre-activated ester. The peptide was cleaved from the resin using a cocktail mixture of 95% (v/v)
trifluoroacetic acid (TFA), 2.5% (v/v) tri-isopropyl silane (TIPS) and 2.5% (v/v) water for 5h. The
cleaved peptide was precipitated with tert-butyl methyl ether (TBME) and centrifuged at 3000 rpm for
10 minutes. After decanting, the peptide was frozen and lyophilized to remove any remaining solvents.
The peptide was purified with reverse phase preparative HPLC, and the purity was checked by
analytical UHPLC. Each of the following peptides synthesized resulted in purity > 95%.
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a) Pyta-AAA-3Pal, 3.1

The linear peptide was synthesized using the general procedure for solid phase peptide synthesis
mentioned above (3.7.5). This afforded pure peptide in the form of white fluffy solid (yield = 0.017
1

g, 30%) ESI HRMS: m/z calculated for C26H33N10O5, 565.2635 observed [M+H]+ 565.2552 H
NMR (400 MHz, DMSO-d6): δ 8.67-8.62 (m, Ar-H + NH of Ala 3, 1H), 8.61-8.59 (m, 1H), 8.52
(s, 1H), 8.17 (d, 3JH-H = 8.0 Hz, 1H), 8.13 (d, 3JH-H = 8.0 Hz, 1H), 8.03 (dt, 3JH-H = 8.0 Hz, 1.2 Hz,
1H), 7.93-7.90 ( m, NH of 3-Pal + Ar-H, 2H), 7.84 (d, 3JH-H = 4.0 Hz, NH of Ala 1, 1H), 7.72 (dd,
3

JH-H = 8.0 Hz, 5.2 Hz, 1H), 7.39 (s, 1H), 7.37-7.33 (m, 1H), 7.22 (s, 1H), 5.23 (s, 2H), 4.49 (m,

α CH of 3Pal, 1H), 4.34 (quint, 3JH-H = 12.0 Hz, 8.0 Hz, CH of Ala 3, 1H), 4.22 (quint, 3JH-H = 12.0
Hz, 8.0 Hz, α CH of Ala 2, 1H), 4.10 (quint, 3JH-H = 12.0 Hz, 8.0 Hz, α CH of Ala 1, 1H), 3.05
(dd, 2JH-H = 12.0 Hz, 3JH-H = 6.1 Hz, ß H of 3-Pal, 1H), 3.03 (dd, 2JH-H = 12.0 Hz, 3JH-H = 6.1 Hz, ß’
H of 3-Pal, 1H), 1.23 (d, 3JH-H = 4.0 Hz, CH3 of Ala 3, 3H), 1.16 (d, 3JH-H = 4.0 Hz, CH3 of Ala 2,
3H), 1.07 (d, 3JH-H = 4.0 Hz, CH3 of Ala 1, 3H).
b) Pyta-RGD-3Pal, 3.2

The linear peptide was synthesized using the general procedure for solid phase peptide synthesis
mentioned above (3.7.5). This afforded pure peptide in the form of white fluffy solid (yield = 0.020
1

g, 29 %) ESI HRMS: m/z calculated for C29H38N13O7, 680.3017 observed [M+H]+ 680.3047, H
NMR (400 MHz, DMSO-d6): δ 8.72 (d, NH of Arg, 3JH-H = 8.0 Hz, 1H), 8.60 (m, 3H), 8.53 (s, 1H),
8.42 (t, NH of Gly, 3JH-H = 8.0 Hz, 1H), 8.22 (d, NH of Asp, 3JH-H = 8.0 Hz, 1H), 8.09-8.02 (m, NH
of 3-Pal + Ar-H, 3H), 7.91 ( dt, 3JH-H = 8.0 Hz, 4.0 Hz , 1H), 7.65 (m, 1H), 7.55 (t, NH next to δ
CH2 of Arg, 3JH-H = 4.0 Hz, 1H), 7.38-7.33 (m, 2H), 7.29 (s, 1H), 5.27 (s, 2H), 4.52-4.44 (m, α CH
of 3Pal and Asp, 3H), 4.43-4.38 (m, α CH of Arg, 2H), 3.80-3.67 (m, CH2 of Gly, 3H), 3.20 (dd,
2

JH-H = 16.0 Hz, 3JH-H = 8.0 Hz, ß H of CH2 of 3-Pal, 1H), 3.12 (quint, 3JH-H = 8.0 Hz, δ CH2 of Arg,

3H), 2.93 (dd, 2JH-H = 12.0 Hz, 3JH-H = 8.0 Hz, ß’ H of 3pal, 1H), 2.62 (dd, ß H of CH2 of Asp, 2JHH=

16.0 Hz, 3JH-H = 8.0 Hz, 1H), 2.42 (dd, b’ H of CH2 of Asp, 2JH-H = 16.0 Hz, 3JH-H = 8.0 Hz,

1H) 1.79 -1.70 (m, ß H of CH2 of Arg, 1H), 1.63-1.50 (m, ß’ H of CH2 of Arg + γ CH2 of Arg, 4H).
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c) Pyta-AAAA-3Pal, 3.3

The linear peptide was synthesized using the general procedure for solid phase peptide synthesis
mentioned above (3.7.5). This afforded pure peptide in the form of white fluffy solid (yield = 0.015
1

g, 24 %) ESI-HRMS: m/z calculated for C29H38N11O6, 636.3007 observed [M+H]+ 636.2969, H
NMR (400 MHz, DMSO-d6): δ 8.65 (d, 3JH-H = 4.0 Hz, NH of Ala 4, 1H), 8.59 (bs, 2H), 8.51 (s,
1H), 8.21 (d, 3JH-H = 8.0 Hz, 1H), 8.03 (t, 3JH-H = 8.0 Hz, 2H), 7.92-7.83 (m, NH of Ala 1, Ala 2
and 3-Pal, 4H), 7.65 (bs, 1H), 7.38 (s, 1H), 7.34 (s, 1H), 7.21 (s, 1H), 5.22 (s, 2H), 4.47 (m, α CH
of 3Pal,1H), 4.34 (quint, 3JH-H = 12.0 Hz, 4.0 Hz, CH of Ala 4, 1H), 4.24 (m, α CH of Ala 3, 1H),
4.18 (m, α CH of Ala 2, 1H), 4.12 (m, α CH of Ala 1, 1H), 3.15 (m, ß H of 3-Pal, 1H), 2.91 (m,
ß’ H of 3-Pal, 1H), 1.24 (d, 3JH-H = 4.0 Hz, CH3 of Ala 4, 3H), 1.20 (d, 3JH-H = 4.0 Hz, CH3 of Ala
3, 3H), 1.12 (d, 3JH-H = 4.0 Hz, CH3 of Ala 1 and Ala 2, 6H).
d) Pyta-AAAAA-3Pal, 3.4

The linear peptide was synthesized using the general procedure for solid phase peptide synthesis
mentioned above (3.7.5). This afforded pure peptide in the form of white fluffy solid (yield = 0.021
1

g, 30 %) ESI-HRMS: m/z calculated for C32H43N12O7, 707.3378 observed [M+H]+ 707.3381, H
NMR (400 MHz, DMSO-d6): δ 8.65 (d, 3JH-H = 8.0 Hz, NH of Ala 5, 1H), 8.59 (m, 1H), 8.57-8.53
(m, 2H), 8.51 (s, 1H), 8.21 (d, NH of Ala 4, 3JH-H = 8.0 Hz, 1H), 8.02 (d, , 3JH-H = 4.0 Hz, H), 7.927.86 (m, NH of Ala 1, Ala 2, Ala 3, 3-Pal, 4H),7.57 (m, 1H), 7.38 (bs, 1H), 7.36-7.32(m, 1H), 7.23
(s, 1H), 7.20 (s, 1H), 7.10 (s, 1H), 6.97 (s, 1H), 5.22 (s, 2H), 4.48-4.43 (m, 1H), 4.34 (quint, 3JH-H
= 12.0 Hz, 4.0 Hz, CH of Ala 5, 1H), 4.27- 4.17 (m, α CH of Ala 2, Ala 3 and Ala 4, 3H), 4.11
(quint, 3JH-H = 12.0 Hz, 4.0 Hz, CH of Ala 1, 1H), 3.16-3.11 (m, ß H of 3-Pal, 1H), 2.92-2.87 (m,
ß’ H of 3-Pal, 1H), 1.24 (d, 3JH-H = 8.0 Hz, CH3 of Ala 5, 3H), 1.22 (d, 3JH-H = 8.0 Hz, CH3 of Ala
4, 3H), 1.21 (d, 3JH-H = 8.0 Hz, CH3 of Ala 3), 1.16 (d, 3JH-H = 8.0 Hz, CH3 of Ala 2, 3H), 1.11 (d,
3

JH-H = 8.0 Hz, CH3 of Ala 1)

e) Pyta-AaA-3Pal, 3.5

The linear peptide was synthesized using the general procedure for solid phase peptide synthesis
mentioned above (3.7.5). This afforded pure peptide in the form of white fluffy solid (yield = 0.010
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1

g, 18 %) ESI-HRMS: m/z calculated for C26H33N10O5, 565.2635 observed [M+H]+ 565.2552 H
NMR (400 MHz, DMSO-d6): δ 8.67-8.62 (m, Ar-H + NH of Ala 3, 1H), 8.60-8.58 (m, 2H), 8.52
(s, 1H), 8.38 (d, NH of Ala 2, 3JH-H = 8.0 Hz, 1H), 8.13 (d, 3JH-H = 8.0 Hz, 1H), 8.05-8.02 (m, NH
of Ala 1, 1H), 8.00 (m, 1H), 7.96 ( d, 3JH-H = 12.0 Hz, NH of 3-Pal, 1H), 7.90 (dt, 3JH-H = 8.0 Hz,
1.8 Hz, 1H), 7.72-7.68 (m, 1H), 7.28 (s, 1H), 7.21 (s, 1H), 5.23 (s, 2H), 4.49 - 4.44 (m, α CH of
3-Pal, 1H), 4.36 (quint, 3JH-H = 16.0 Hz, 8.0 Hz, CH of Ala 3, 1H), 4.18 (quint, 3JH-H = 16.0 Hz, 8.0
Hz, α CH of Ala 2, 1H), 4.05 (quint, 3JH-H = 16.0 Hz, 8.0 Hz, α CH of Ala 1, 1H), 3.09 (dd, 2JH-H
= 16.0 Hz, 3JH-H = 3.8 Hz, ß H of 3-Pal, 1H), 3.07 (dd, 2JH-H = 12.0 Hz, 3JH-H = 4.2 Hz, ß’ H of 3Pal, 1H), 1.26 (d, 3JH-H = 8.0 Hz, CH3 of Ala 3, 3H), 1.18 (d, 3JH-H = 8.0 Hz, CH3 of Ala 2, 3H),
1.00 (d, 3JH-H = 8.0 Hz, CH3 of Ala 1, 3H).
f) Bipyd-AAA-3Pal, 3.6

The linear peptide was synthesized using the general procedure for solid phase peptide synthesis
mentioned above (3.7.5). This afforded pure peptide in the form of white fluffy solid (yield = 0.012
1

g, 24 %) ESI-HRMS: m/z calculated for C28H33N8O5, 561.2574 observed [M+H]+ 561.2532 H
NMR (400 MHz, DMSO-d6): δ 9.06 (d, 3JH-H = 8.0 Hz, NH of Ala 3, 1H), 8.84 (d, 3JH-H = 8.0 Hz,
1H), 8.82 (m, 1H), 8.74 (m, 1H), 8.71 (m, 1H), 8.68 (d, 3JH-H = 2.0 Hz, 1H), 8.43 ( dt, 3JH-H = 8.0
Hz, 1.1 Hz, 1H), 8.24 (dt, JH-H = 8.0 Hz, 1H), 8.01 (td, 3JH-H = 8.0 Hz, 5.2 Hz, 1H), 7.96 (d, 3JH-H =
8.0 Hz, 1H), 7.88 (d, 3JH-H = 4.0 Hz, 1H), 7.86 (dd, 3JH-H = 5.0 Hz, 1.0 Hz, 1H), 7.82 (dd, 3JH-H =
8.0 Hz, 4.3 Hz, 1H), 7.52 (m, 1H), 7.41 (bs, 1H), 7.26 (bs, 1H), 4.55 - 4.47 (m, α CH of 3Pal and
Ala 3, 2H), 4.26 (quint, 3JH-H = 12.0 Hz, 4.0 Hz, CH of Ala 2, 1H), 4.13 (quint, 3JH-H = 12.0 Hz,
4.0 Hz, α CH of Ala 1, 1H), 3.10 (dd, 2JH-H = 12.0 Hz, 3JH-H = 2.3 Hz, ß’ H of CH2 of 3pal, 1H),
3.09 (dd, 2JH-H = 12.0 Hz, 3JH-H = 1.7 Hz, ß H of CH2 of 3pal, 1H), 1.37 (d, 3JH-H = 8.0 Hz, CH3 of
Ala 3, 3H), 1.20 (d, 3JH-H = 8.0 Hz, CH3 of Ala 2, 3H), 1.14 (d, 3JH-H = 8.0 Hz, CH3 of Ala 1, 3H).
g) Bipyd-RGD-3Pal, 3.7

The linear peptide was synthesized using the general procedure for solid phase peptide synthesis
mentioned above (3.7.5). This afforded pure peptide in the form of white fluffy solid (yield = 9
1

mg, 13 %) ESI-HRMS: m/z calculated for C31H38N11O7, 676.2956 observed [M+H]+ 676.2927, H
NMR (400 MHz, DMSO-d6): δ 9.11 (d, NH of Arg, 3JH-H = 8.0 Hz, 1H), 8.43-8.38 (m, NH of Gly
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+ Ar-H, 2H), 8.17 (d, 3JH-H = 8.0 Hz, 1H), 8.13-8.08 (m, NH of Asp + Gly, 2H), 8.00 (td, 3JH-H =
8.0 Hz, 4.0 Hz, 1H), 7.87 (dd, 3JH-H = 8.0 Hz, 4.0 Hz, 3H), 7.71(m, 1H), 7.57( t, NH next to δ CH2
of Arg , 3JH-H = 4.0 Hz , 1H), 7.51 (m, 1H), 7.30 (d, 3JH-H = 4.0 Hz, 1H), 4.58 - 4.44 (m, 4H), 3.74
(m, CH2 of Gly, 2H), 3.21 (dd, 2JH-H = 8.0 Hz, 3JH-H = 4.0 Hz, ß H of CH2 of 3-Pal, 1H), 3.14 (quint,
3

JH-H = 8.0 Hz, δ CH2 of Arg, 2H), 2.95 (dd, 2JH-H = 16.0 Hz, 3JH-H = 12.0 Hz, ß’ H of 3-Pal, 1H),

2.65 (dd, ß H of CH2 of Asp, 2JH-H = 16.0 Hz, 3JH-H = 8.0 Hz, 1H), 2.44 (dd, ß’ H of CH2 of Asp,
2

JH-H = 16.0 Hz, 3JH-H = 8.0 Hz, 1H) 1.81-1.72 (m, ß CH2 of Arg, 1H), 1.63-1.53 (m, γ CH2 of Arg,

2H).
3.7.6

Metal coordination

1) [Re(CO)3(Pyta-AAA-3Pal-NH2]OTf , 3.8
The purified linear peptide, 3.1 (50.0 mg, 0.088 mmol) was coordinated [Re(CO)3(OH2)3]OTf (797 μL
of 0.1 M solution, 0.0797 mmol) in water (6 mL). The solution was stirred for 2 hours at 50 °C. Upon
completion of reaction, the crude mixture was lyophilized and purified by preparative HPLC. (Linear
gradient of 35-95 % of solvent C in B) (yield = 19.5 mg, 27%), ESI-HRMS: m/z calculated for
1

C29H32N10O8185/187Re, 835.1962; observed [M]+ 835.2040. H NMR (400 MHz, DMSO-d6): δ 9.27

(d, 3JH-H = 8.0 Hz, 1H), 9.01 (d, 3JH-H = 4.0 Hz, 1H), 8.86 (d, NH of Ala 3, 3JH-H = 4.0 Hz, 1H), 8.60
(m, 1H), 8.58 (s, 1H), 8.43 - 8.41 (m, 1H), 8.40 - 8.38 (m, 1H), 8.33 (td, 3JH-H = 4.0 Hz, 1.5 Hz,
1H), 8.23 (dd, NH of Ala 2, 3JH-H = 8.0 Hz, 4.0 Hz, 1H), 8.02 (d, 3JH-H = 8.0 Hz, 1H), 7.91 ( d, NH
of 3-Pal, 3JH-H = 8.0 Hz, 1H), 7.86 (dd, NH of Ala 1, 3JH-H = 12.0 Hz, 8.0 Hz, 1H), 7.69 - 7.65(m,
1H), 7.64-7.61 (m, 1H), 7.41 (s, 1H), 7.22 (s, 1H), 5.51 (s, 2H), 4.51- 4.44 (m, α CH of 3Pal,1H),
4.40 - 4.34 (m, α CH of Ala 3, 1H), 4.25 (quint, 3JH-H = 12.0 Hz, 8.0 Hz, α CH of Ala 2, 1H), 4.12
(quint, 3JH-H = 12.0 Hz, 8.0 Hz, α CH of Ala 1, 1H), 3.06 (dd, 2JH-H = 12.0 Hz, 3JH-H = 6.1 Hz, ß H
of 3-Pal, 1H), 3.04 (dd, 2JH-H = 12.0 Hz, 3JH-H = 6.1 Hz, ß’ H of 3pal, 1H), 1.26 (d, 3JH-H = 8.0 Hz,
CH3 of Ala 3, 3H), 1.19 (d, 3JH-H = 8.0 Hz, CH3 of Ala 2, 3H), 1.10 (d, 3JH-H = 8.0 Hz, CH3 of Ala
1, 3H)
2) [Re(CO)3(Pyta-RGD-3Pal-NH2]OTf , 3.9
The purified linear peptide, 3.2 (120.0 mg, 0.177 mmol) was coordinated [Re(CO)3(OH2)3]OTf (1.59
mL of 0.1 M solution, 0.159 mmol) in water (10 mL). The solution was stirred for 2 hours at 50 °C.
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Upon completion of reaction, the crude mixture was lyophilized and purified by preparative HPLC.
(Linear gradient of 25-80 % of solvent C in B) (yield = 0.058 g, 34 %), ESI-LCMS: m/z calculated for
1

C32H37N13O10185/187Re, 950.2344; observed [M + H]+ 950.2310 H NMR (400 MHz, DMSO-d6): δ

9.25 (S, 1H), 9.00 (m, 1H), 8.89 (d, NH of Arg, 3JH-H = 8.0 Hz, 1H), 8.57 (m, 2H), 8.45 (d, NH of
Gly, 3JH-H = 4.0 Hz, 1H), 8.38 (m, 1H), 8.33 (td, 3JH-H = 8.0 Hz, 4.0 Hz, 1H), 8.22 (dd, NH of Asp,
3

JH-H = 8.0 Hz, 4.0 Hz, 1H ), 8.06(dd, 3JH-H = 8.0 Hz, 4.0 Hz, NH of 3-Pal, 1H), 7.98 ( d, 3JH-H = 8.0

Hz, 1H), 7.69-7.65 (m, 1H), 7.62-7.56 (m, 1H), 7.51 (t, 3JH-H = 8.0 Hz, NH next to γ CH2 of Arg
,1H), 7.34 (s, 1H), 7.28 (s, 1H), 5.54 (s, 2H), 4.52-4.37 (m, αCH of 3Pal, Arg, Asp, 6H), 3.80-3.68
(m, CH2 of Gly, 2H), 3.18 (m, β H of CH2 of 3-Pal, 1H), 3.11 (m, δ CH2 of Arg, 2H), 2.93 (dd,
2

JH-H = 12.0 Hz, 3JH-H = 8.0 Hz, ß’ H of 3pal, 1H), 2.67-2.59 (m, β H of CH2 of Asp, 1H), 2.42 (m,

β’ H of CH2 of Asp,, 1H) 1.82-1.69 (m, β H of CH2 of Arg, 1H), 1.67-1.49 (m, β’ H of CH2 of Arg
+ γ CH2 of Arg, 4H).
3) [Re(CO)3 Pyta-AAAA-3Pal], 3.10
The purified linear peptide, (3.3), (83.0 mg, 0.131 mmol) was coordinated [Re(CO)3(OH2)3]OTf (1.17
mL of 0.1 M solution, 0.117 mmol) in water (8 mL). The solution was stirred for 2 hours at 50 °C.
Upon completion of reaction, the crude mixture was lyophilized and purified by preparative HPLC.
(Linear gradient of 35-95 % of solvent C in B) (yield = 0.023 g, 21 %) ESI-LCMS: m/z calculated
1

for C32H37N11O9185/187Re, 906.2333 observed [M+H]+ 906.2170, H NMR (400 MHz, DMSO-d6):
δ 9.27 (s, 1H), 9.01 (d, 3JH-H = 8.0 Hz, 1H), 8.86 (m, NH of Ala 4, 1H), 8.53 (bs, 1H), 8.42-8.38
(m, 1H), 8.34 (m, 1H), 8.26 (dd, NH of Ala 3, 3JH-H = 8.0 Hz, 4 Hz, 1H), 7.91-7.86 (m, NH of Ala
1, Ala 2 and 3-Pal, 4H), 7.70-7.66 (m, 1H), 7.50 (bs, 1H), 7.40 (s, 1H), 7.20 (s, 1H), 5.51 (s, 2H),
4.49 - 4.44 (m, α CH of 3Pal, 1H), 4.41-4.36 (m, CH of Ala 4, 1H), 4.27 (quint, 3JH-H = 12.0
Hz, 4.0 Hz, α CH of Ala 3, 1H), 4.24 - 4.11 (m, α CH of Ala 2 and Ala 1, 2H), 3.01 (dd, 2JH-H =
16.0 Hz, 3JH-H = 5.9 Hz, ß H of 3-Pal, 1H), 2.99 (dd, 2JH-H = 16.0 Hz, 3JH-H = 6.0 Hz, ß’ H of 3-Pal,
1H), 1.28 (d, 3JH-H = 4.0 Hz, CH3 of Ala 4, 3H), 1.22 (d, 3JH-H = 4.0 Hz, CH3 of Ala 3, 3H), 1.161.13 (d, 3JH-H = 4.0 Hz, CH3 of Ala 1 and Ala 2, 6H).
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4) [Re(CO)3 Pyta-AAAAA-3Pal], 3.11
The purified linear peptide, (3.4), (85.0 mg, 0.120 mmol) was coordinated [Re(CO)3(OH2)3]OTf (1.08
mL of 0.1 M solution, 0.1082 mmol) in water (8 mL). The solution was stirred for 2 hours at 50 °C.
Upon completion of reaction, the crude mixture was lyophilized and purified by preparative HPLC.
(Linear gradient of 35-95 % of solvent C in B) (yield = 0.015g, 13 %) ESI-HRMS: m/z calculated
1

for C35H42N12O10185/187Re, 977.2705 observed [M+H]+ 977.2711, H NMR (400 MHz, DMSO-d6):
δ 9.27 (s, 1H), 9.01 (d, 3JH-H = 8.0 Hz, 1H), 8.87-8.84 (m, NH of Ala 5, 1H), 8.56 (m, 2H), 8.41
(m, 1H), 8.33 (m, 1H), 8.26 (dd, NH of Ala 4, 3JH-H = 8.0 Hz, 4.0 Hz, 1H), 7.97 (d, 3JH-H = 8.0 Hz,
1H), 7.92-7.87 (m, NH of Ala 1, Ala 2, Ala 3 and 3-Pal, 4H), 7.69-7.65 (m, 1H), 7.60-7.57 (m,
1H), 7.39 (s, 1H), 7.21 (s, 1H), 5.50 (m, 2H), 4.49 - 4.44 (m, α CH of 3Pal, 1H), 4.40-4.36 (m,
CH of Ala 5, 1H), 4.27 (quint, 3JH-H = 12.0 Hz, 8.0 Hz, α CH of Ala 4, 1H), 4.23 - 4.17 (m, α CH
of Ala 2 and Ala 3, 2H), 4.13 (m, 3JH-H = 12.0 Hz, 4.0 Hz, α CH of Ala 1, 1H), 3.01 (dd, 2JH-H =
12.0 Hz, 3JH-H = 5.9 Hz, ß H of 3pal, 1H), 2.99 (dd, 2JH-H = 12.0 Hz, 3JH-H = 6.0 Hz, ß’ H of 3pal,
1H), 1.27 (d, 3JH-H = 4.0 Hz, CH3 of Ala 5, 3H), 1.22 (d, 3JH-H = 4.0 Hz, CH3 of Ala 4, 3H), 1.17 (d,
3

JH-H = 4.0 Hz, CH3 of Ala 1 and Ala 2, 6H), 1.12 (d, 3JH-H = 8.0 Hz, 3H).

5) [Re(CO)3(Pyta-AaA-3Pal-NH2]OTf , 3.12
The purified linear peptide, (3.5), (50.0 mg, 0.088 mmol) was coordinated [Re(CO)3(OH2)3]OTf (797
μL of 0.1 M solution, 0.0797 mmol) in water (8 mL). The solution was stirred for 2 hours at 50 °C.
Upon completion of reaction, the crude mixture was lyophilized and purified by preparative HPLC.
(Linear gradient of 32-95 % of solvent C in B) (yield = 0.016 g, 21% ), ESI-HRMS: m/z calculated for
1

C29H32N10O8185/187Re, 835.1962; observed [M]+ 835.1857 H NMR (400 MHz, DMSO-d6): δ 9.27

(d, 3JH-H = 8.0 Hz, 1H), 9.00 (d, NH of Ala 3, 3JH-H = 4.0 Hz, 1H) 8.83 (dd, 3JH-H = 8.0 Hz, 4.0 Hz,
1H), 8.64 (s, 1H), 8.62 (s, 1H), 8.41 (m, 1H), 8.38-8.31 (m, 2H), 8.13 (d, 3JH-H = 8.0 Hz, 1H), 8.128.09 (m, 2H), 7.97 ( d, 3JH-H = 8.0 Hz, 1H), 7.69-7.65 (m, 2H), 7.25 (d, 3JH-H = 12.0 Hz, 1H), 5.535.49 (m, 2H), 4.50- 4.37 (m, α CH of 3Pal and Ala 3, 2H), 4.19 (quint, 3JH-H = 12.0 Hz, 8.0 Hz,
α CH of Ala 2, 1H), 4.05 (quint, 3JH-H = 12.0 Hz, 8.0 Hz, α CH of Ala 1, 1H), 3.26-3.19 (m, ß H
of 3pal, 1H), 3.03-2.95 (m, ß’ H of 3pal, 1H), 1.28 (d, 3JH-H = 8.0 Hz, CH3 of Ala 3, 3H), 1.19 (d,
3

JH-H = 8.0 Hz, CH3 of Ala 2, 3H), 1.03 (d, 3JH-H = 8.0 Hz, CH3 of Ala 1, 3H)
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6) Re(CO)3[Bipyd-AAA-3Pal], 3.13
The purified linear peptide (3.6), (60.0 mg, 0.107 mmol) was coordinated [Re(CO)3(OH2)3]OTf (963
μL of 0.1 M solution, 0.096 mmol) in water (6 mL). The solution was stirred for 2 hours at 50 °C.
Upon completion of reaction, the crude mixture was lyophilized and purified by preparative HPLC.
(Linear gradient of 35-95 % of solvent C in B), (yield = 0.013g, 15%) ESI-HRMS: m/z calculated
1

for C31H32N8O8185/187Re, 831.1901 observed [M+H]+ 831.1965 H NMR (400 MHz, DMSO-d6): δ
9.25- 9.22 (m, NH of Ala 3, 2H), 9.10 (m, 1H), 9.04 (bs, 1H), 8.81 (t, 3JH-H = 8.0 Hz, 1H), 8.62
(bs, 2H), 8.45-8.40 (m, 1H), 8.26 (m, 1H), 8.10-8.08 (m, 1H), 7.94 (d, NH of 3-Pal, 3JH-H = 8.0 Hz,
1H), 7.88 ( d, 3JH-H = 4.0 Hz, 1H), 7.83 (t, NH of Ala 1, 3JH-H = 8.0 Hz, 1H), 7.68 (t, 3JH-H = 8.0 Hz,
1H), 7.42 (s, 1H), 7.23 (s, 1H), 4.56 (quint, α CH of Ala 3, 3JH-H = 16.0 Hz, 8.0 Hz, 2H), 4.534.47 (m, 1H), 4.27 (quint, 3JH-H = 12.0 Hz, 4.0 Hz, α CH of Ala 2, 1H), 4.15 (quint, 3JH-H = 12.0
Hz, 8.0 Hz, α CH of Ala 1, 1H), 3.05 (dd, 2JH-H = 12.0 Hz, 3JH-H = 6.1 Hz, ß’ H of CH2 of 3-Pal,
1H), 3.04 (dd, 2JH-H = 12.0 Hz, 3JH-H = 6.1 Hz, ß H of CH2 of 3-Pal, 1H), 1.39 (d, 3JH-H = 8.0 Hz,
CH3 of Ala 3, 3H), 1.21 (d, 3JH-H = 8.0 Hz, CH3 of Ala 2, 3H), 1.14 (d, 3JH-H = 8.0 Hz, CH3 of Ala
1, 3H).
7) [Re(CO)3(Bipyd-RGD-3Pal-NH2]OTf, 3.14
The purified linear peptide, (3.7), (35.0 mg, 0.051 mmol) was coordinated [Re(CO)3(OH2)3]OTf (465
μL of 0.1 M solution, 0.0465 mmol) in water (10 mL). The solution was stirred for 2 hours at 50 °C.
Upon completion of reaction, the crude mixture was lyophilized and purified by preparative HPLC.
(Linear gradient of 36-95 % of solvent C in B) (yield = 12 mg, 25 %), ESI-LCMS: m/z calculated for
1

C34H37N11O10185/187Re, 946.2283; observed [M + H]+ 946.2487 H NMR (400 MHz, DMSO-d6): δ

9.32 (d, NH of Arg, 3JH-H = 8.0 Hz, 1H), 9.23 (dd, 3JH-H = 4.0 Hz, 2.0 Hz, 1H), 9.11 (m, 1H), 9.04
(m, 1H), 8.79 (dd, 3JH-H = 8.0 Hz, 4.0 Hz 1H), 8.58 - 8.48 (m, NH of Gly + Ar-H, 3JH-H = 4.0 Hz,
2H), 8.43 (m, 1H), 8.18 (d, NH of Asp, 3JH-H = 8.0 Hz, 1H), 8.11 (m, 1H ), 8.05 (d, 3JH-H = 8.0 Hz,
NH of 3-Pal, 1H), 7.93 ( bs, 1H), 7.84 (m, 1H), 7.56 (m, NH next to γ CH2 of Arg, 1H), 7.32 (s,
1H), 7.26 (s, 1H), 4.61- 4.50 (m, α CH of Arg and Asp, 2H), 4.44 (m, αCH of 3-Pal, 2H), 3.76 (m,
CH2 of Gly, 2H), 3.17-3.14 (m, β H of CH2 of 3-Pal + δ CH2 of Arg, 3H), 2.94-2.88 (m, β’ H of
CH2 of 3-Pal, 1H), 2.65 (dd, 2JH-H = 16.0 Hz, 3JH-H = 8.0 Hz, ß’ H of Asp, 1H), 2.45 (dd, 2JH-H =
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16.0 Hz, 3JH-H = 8.0 Hz, ß H of Asp, 1H), 1.81-1.71 (m, β CH2 of Arg, 2H), 1.67-1.56 (m, γ CH2
of Arg, 2H).

8) 99mTc(CO)3-Pyta-AAA-3Pal, 3.15
Isolink kit containing sodium potassium tartrate, sodium tetraborate, sodium carbonate, and
sodium boranocarbonate was dissolved in 1 mL of distilled water. To it was added 1093 MBq
(0.300 mL) of [99mTc]-pertechnetate. This was stirred at 110 °C for 3.5 mins in the microwave
reactor. After 3.5 min, 200 μL of 1 M HCl was added and was allowed to stand for 5 min. 180
MBq (200 μL) was then added to (3.1) (0.5 mg, 8.8 μmol) and was diluted with H2O to total
volume of 1 mL. This reaction was carried out in the microwave reactor at 60 °C for 30 min. HPLC
analysis showed retention time of 9.80 and 10.23 min at a linear gradient of 25-75% solvent C in
B for 15 min. The labelled conformers were then purified using a Waters Sep-Pak Plus C18
Cartridge. This resulted in a 24% and 44% decay corrected radiochemical yield for the respective
conformers.

Circular Dichroism spectroscopy
CD was carried out on a Jasco J-810 spectropolarimeter and recorded in the range of 180-260 nm.
All the linear and cyclic peptides (>90% purity, lyophilized) were dissolved in Milli-Q water to a
concentration of 0.25 mg/mL. The measurement was carried out at 20ᴼ C, using a quartz cuvette
with a path length of 1 mm. The instrument measured at a scanning speed of 100 nm/min with a
response rate of 0.5s. A blank solution of Milli-Q water was run before the measurements. Graph
pad Prism (version 6.0c) was used to plot the graphs.
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Chapter Four
4

Conclusion

In recent years, cyclic peptides have achieved significant success as diagnostics and therapeutics.
Constrained geometry of the cyclic peptides leads to improved properties like enhanced in vivo
stability, good binding affinity and target selectivity. This gives them an edge over their linear
counterparts and thus find application in the development of pharmaceutical products.1 Peptides
can be cyclized by various methods like head to tail, head to side chain, side chain to side chain
cyclization or through formation of a disulfide bond. In addition to these classical methods,
cyclization can be induced in peptides through metal coordination. The scope of the thesis is
limited to the ability of group 7 metals, Re and the radioactive 99mTc, to induce cyclization in linear
peptides.
Previously, Simpson et.al cyclized a pentapeptide sequence Ac-HAAAH using [Re(CO)3(OH2)3]
OTf.2 Terminal histidine amino acids were used as a chelator for coordinating with the metal
tricarbonyl core. The tri-alanine sequence was selected due to the ability of alanine to form stable
helices in water.3 Histidine was used as a mono and a bidentate ligand where the monodentate
coordination took place using the nitrogen of the imidazole side chain of histidine and bidentate
chelation using the nitrogen of the imidazole and oxygen of the carboxylic acid present on the
peptide C-terminus. This led to formation of a cyclic peptide where a turn was induced using the
chelation of the ligands to the metal core, creating a 2+1 chelation complex. However, this system
had numerous linkage isomers due to histidine having multiple coordinating sites. Separation of
the isomers proved to be a challenging task. It was thus critical to select a chelator having lesser
coordinating sites. Patel et.al used an unnatural amino acid 3-pyridyl alanine (3-Pal) along with a
synthetic ligand pyridyl triazole (pyta) to cyclize the biologically relevant peptide sequence pytaRGD-3Pal.4 The sequence RGD was chosen due its increased affinity for the integrin αvβ3 which
is overexpressed in several cancer types5. The design involved the use of pyta as a bidentate ligand
with its two-nitrogen atoms on the triazole ring chelating the metal and 3-pyridyl alanine as a
monodentate ligand. The use of this unnatural amino acid and synthetic ligand combination, along
with natural amino acid sequence RGD, led to formation of a peptidomimetic scaffold which
would have the potential to improve the binding properties of the RGD motif.
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The goal of this thesis was to apply this concept of using unnatural amino acid and synthetic ligand
as chelators, for cyclization of the linear peptide sequence X-Ala-Ala-Ala-X (X= unnatural amino
acid/synthetic ligand). We used the peptide sequence Ala-Ala-Ala since alanine is known to have
higher propensity to form an alpha-helix.6 Furthermore, alanine being one of the simplest amino
acids, would be used as a model sequence to study the effect of metal based cyclization on the
pentapeptide. It would then be possible to replace it with the biological relevant peptide sequence
RGD.
Apart from pyta, we also aimed to use a different bidentate chelator 2,2’-bipyridine-4-carboxylic
acid and study its effect on coordination. Both pyridyl triazole acetic acid and 2,2’-bipyridine-4carboxylic acid forms a 5-membered ring with the metal complex, which considered to be a more
stable ring size in contrast to the 7 membered ring formed by histidine as a chelator (Figure 4.1).

a

b

c

Figure 4.1 a) Formation of a 7 membered ring with histidine as a chelator, b), c) 5 membered
ring formed by pyridyl triazole acetic acid and 2,2’-bipyridine-4-carboxylic acid
Prior to moving towards cyclization, it was critical to optimize the reaction conditions used for
rhenium coordination. The replication of the coordination reaction conditions used previously by
Simpson et.al and Patel et.al did not lead to effective yield of cyclic product. Thus, chapter two
describes the optimization methods carried out to improve the yield of cyclic peptide. Temperature
and time proved to be the essential factors which helped in reaction optimization. It was observed
that on increasing the temperature, there was an increase in the yield of the cyclic product.
However, excessive heat leads to formation of conformers/isomers which were observed on
analysis of the crude product on the LCMS. In order to effectively increase the yield as well keep
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the formation of the less dominant conformer/isomer to the minimum, a reaction condition was
decided based on the quantification done by UHPLC. In addition to time and temperature, factors
like change in solvents and presence/absence of base was also taken in consideration.
It was observed that even after applying optimal conditions, some of the linear peptide would still
remain uncyclized. It was then imperative to acknowledge the effect of peptide length on the
cyclization reaction. Assuming that the short pentapeptide would not be flexible enough to form a
turn and chelate the metal in 2+1 fashion, we synthesized the peptide sequences with increasing
length. Thus, peptide sequences pyta-Ala-Ala-Ala-Ala-3pal, pyta-Ala-Ala-Ala-Ala-Ala-3pal were
synthesized. In addition to above mentioned peptides, another peptide sequence pyta-Ala-ala-Ala3pal was synthesized with D-alanine in the center. D-amino acids are known to aid in cyclization
by conformational preorganization.7 All of these linear peptides were cyclized using
[Re(CO)3(OH2)3] OTf and the yields were compared to the pentapeptide sequence pyta-Ala-AlaAla-3Pal. It was observed that a relatively better yield was obtained when using the hexapeptide
sequence having four alanine in the center. In contrast, the other peptide modifications did not
provide any improvement in the yield. The hexapeptide sequence was used for further studies
along with the pentapeptide sequences synthesized using the two different chelators. Peptides were
cyclized using rhenium tricarbonyl core and it was observed that there was formation of a dominant
conformer along with some minor conformer/isomer peaks. Complete separation of the later
eluting conformers through RP-HPLC was not feasible, however, the dominant product was
separated. The dominant conformers from all the cyclization reaction were studied using NMR
spectroscopy and suggested specific changes in chemical shift which proved that the peptide was
coordinated to the metal in 2+1 chelation fashion. Further studies were done using circular
dichroism spectroscopy which revealed a change in conformation in cyclic peptide. This suggests
that a turn was induced in the linear peptide. However, the change in conformation was more
predominant with peptides having pyta as a ligand in comparison to bipyridine. Further
confirmation of the secondary structure was done using variable temperature NMR spectroscopy
which helps in the detection of intramolecular hydrogen bonds. VT NMR spectroscopy studies
suggested the intramolecular hydrogen bonding does take place based on the values of ∆δ/∆T.

We then aimed to cyclize the linear peptide pyta-Ala-Ala-Ala-3Pal using [99mTc (CO)3(OH2)3]+. It
was assumed that rhenium and technetium being in the same group would behave in a similar
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manner and would coordinate to the linear peptide to form the same dominant cyclic conformer.
However, a unique scientific observation was made when technetium, instead of coordinating and
forming the same dominant cyclic product, chelated and formed a cyclic product which corelated
to the other conformer/isomers obtained as minor products in the rhenium coordination reaction.
Though 99mTc (CO)3+ did not coordinate the way we assumed it would, we were still successful in
performing the coordination reaction and cyclizing the linear peptide.
In conclusion, we were able to cyclize the linear peptide sequences using Re/99mTc(CO)3+ metal
coordination creating a 2+1 chelation complex. Future work can involve the use of different
chelators for both C- and N- terminals and observation of the effect of chelation. X-ray crystal
structure studies would be impactful in studying the different conformers/isomers produced due to
cyclization.
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Appendices
Appendix A Chromatographs of selected compounds (UHPLC-MS UV traces)
Pyridyl triazole acetic acid (3)

2,2’-Bipyridine-4-carboxylic acid (8)

80

Pyta-Ala-Ala-Ala-3pal, (3.1)

Pyta-Arg-Gly-Asp-3pal (3.2)
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Pyta-Ala-Ala-Ala-Ala-3pal (3.3)

Bipyd-Ala-Ala-Ala -3pal (3.6)
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Bipyd-Arg-Gly-Asp -3pal (3.7)

Re(CO)3[Pyta-Ala-Ala-Ala-3pal] (3.8)

83

Re(CO)3[Pyta-Arg-Gly-Asp-3pal] (3.9)

Re(CO)3[Pyta-Ala-Ala-Ala-Ala-3pal] (3.10)
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Re(CO)3[Bipyd-Ala-Ala-Ala-3pal] (3.13)

Re(CO)3[Bipyd-Arg-Gly-Asp-3pal] (3.14)
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Appendix B. 1H and 2D g-COSY, NOESY NMR spectra of linear and cyclic
peptides
1

H NMR spectra of tert-butyl azido acetate (1) in CDCl3 at 400 MHz
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1

H NMR spectra of pyridyl triazole tert-butyl acetate (2) in CDCl3 at 400 MHz

87

1

H NMR spectra of pyridyl triazole acetic acid (pyta) (3) in DMSO-d6 at 400 MHz
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1

H NMR spectra of 4-Methyl-2-bromopyridine carboxylate (6) in CDCl3 at 400 MHz

89

1

H NMR spectra of 4-Methyl-2,2’-bipyridine carboxylate (7) in CDCl3 at 400 MHz
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13

C NMR spectra of 4-Methyl-2,2’-bipyridine carboxylate (7) in CDCl3 at 400 MHz
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1

H NMR spectra of 2,2’-Bipyridine-4-carboxylic acid (8) in DMSO-d6 at 400 MHz
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13

C NMR spectra of 2,2’-Bipyridine-4-carboxylic acid (8) in DMSO-d6 at 400 MHz
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1

H NMR spectra of 3-pyridyl alanine methyl ester (4) in DMSO-d6 at 400 MHz

94

1

H NMR spectra of Boc-Ala-3Pal-OMe (2.1) in CDCl3 at 400 MHz
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1

H NMR spectra of Boc-Ala-Ala-3Pal-OMe (2.2) in CDCl3 at 400 MHz
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1

H NMR spectra of Boc-Ala-Ala-Ala-3Pal-OMe (2.3) in CDCl3 at 400 MHz
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1

H NMR spectra of pyta-Ala-Ala-Ala-3Pal (3.1) in DMSO-d6 at 400 MHz
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g-COSY NMR spectra of pyta-Ala-Ala-Ala-3Pal (3.1) in DMSO-d6 at 400 MHz
Ar-H + NH of Alanine (1-3), 3-Pal

α CH’s
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CH2 - 3Pal

CH3’s of Alanine (1-3)

NOESY NMR spectra of pyta-Ala-Ala-Ala-3Pal (3.1) in DMSO-d6 at 400 MHz

Ar-H + NH of Alanine (1-3), 3-Pal

CH3’s of Alanine (1-3)
α CH’s
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CH2 - 3Pal

1

H NMR spectra of pyta-Arg-Gly-Asp-3Pal (3.2) in DMSO-d6 at 400 MHz
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g-COSY NMR spectra of pyta-Arg-Gly-Asp-3Pal (3.2) in DMSO-d6 at 400 MHz

Ar-H + NH of Arg, Gly, Asp, 3-Pal

α CH’s of Arg, Gly, Asp, 3-Pal
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1

H NMR spectra of pyta-Ala-Ala-Ala-Ala-3Pal (3.3) in DMSO-d6 at 400 MHz
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g-COSY NMR spectra of pyta-Ala-Ala-Ala-Ala-3Pal (3.3) in DMSO-d6 at 400 MHz

CH3’s of Alanine (1- 4)
Ar-H + NH of Alanine (1- 4), 3-Pal

α CH’s
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CH2 - 3Pal

NOESY NMR spectra of pyta-Ala-Ala-Ala-Ala-3Pal (3.3) in DMSO-d6 at 400 MHz

CH3’s of Alanine (1- 4)
α CH’s

Ar-H + NH of Alanine (1- 4), 3-Pal

105

CH2 - 3Pal

1

H NMR spectra of pyta-Ala-Ala-Ala-Ala-Ala-3Pal (3.4) in DMSO-d6 at 400 MHz
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g-COSY NMR spectra of pyta-Ala-Ala-Ala-Ala-Ala-3Pal (3.4) in DMSO-d6 at 400 MHz

CH3’s of Alanine (1- 5)

Ar-H + NH of Alanine (1- 5), 3-Pal

CH2 - 3Pal
α CH’s
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1

H NMR spectra of pyta-Ala-ala-Ala-3Pal (3.5) in DMSO-d6 at 400 MHz
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g- COSY NMR spectra of pyta-Ala-ala-Ala-3Pal (3.5) in DMSO-d6 at 400 MHz

CH3’s of Alanine (1- 3)

Ar-H + NH of Alanine (1- 3), 3-Pal
α CH’s CH2 - 3Pal
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NOESY NMR spectra of pyta-Ala-ala-Ala-3Pal (3.5) in DMSO-d6 at 400 MHz

CH3’s of Alanine (1- 3)

Ar-H + NH of Alanine (1- 3), 3-Pal
α CH’s

110

CH2 - 3Pal

1

H NMR spectra of Bipyd-Ala-Ala-Ala-3Pal (3.6) in DMSO-d6 at 400 MHz

111

g-COSY NMR spectra of Bipyd-Ala-Ala-Ala-3Pal (3.6) in DMSO-d6 at 400 MHz

CH3’s of Alanine (1- 3)
Ar-H + NH of Alanine (1- 3), 3-Pal

α CH’s CH2 - 3Pal
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NOESY NMR spectra of Bipyd-Ala-Ala-Ala-3Pal (3.6) in DMSO-d6 at 400 MHz

CH3’s of Alanine (1- 3)
Ar-H + NH of Alanine (1- 3), 3-Pal

α CH’s

113

CH2 - 3Pal

1

H NMR spectra of Bipyd-Arg-Gly-Asp-3Pal (3.7) in DMSO-d6 at 400 MHz

114

g-COSY NMR spectra of Bipyd-Arg-Gly-Asp-3Pal (3.7) in DMSO-d6 at 400 MHz

Ar-H + NH of Arg, Gly, Asp, 3-Pal
α CH’s of Arg, Gly, Asp, 3Pal
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1

H NMR spectra of Re(CO)3[pyta-Ala-Ala-Ala-3Pal] (3.8) in DMSO-d6 at 400 MHz
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g-COSY NMR spectra of Re(CO)3[pyta-Ala-Ala-Ala-3Pal] (3.8) in DMSO-d6 at 400 MHz

CH3’s of Alanine (1- 3)

Ar-H + NH of Alanine (1- 3), 3-Pal
α CH’s CH2 - 3Pal
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NOESY NMR spectra of Re(CO)3[pyta-Ala-Ala-Ala-3Pal] (3.8) in DMSO-d6 at 400 MHz

CH3’s of Alanine (1- 3)

Ar-H + NH of Alanine (1- 3), 3-Pal
α CH’s
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CH2 - 3Pal

1

H NMR spectra of Re(CO)3[pyta-Arg-Gly-Asp-3Pal] (3.9) in DMSO-d6 at 400 MHz

119

g-COSY NMR spectra of Re(CO)3[pyta-Arg-Gly-Asp-3Pal] (3.9) in DMSO-d6 at 400 MHz

Ar-H + NH of Arg, Gly, Asp, 3-Pal

120

α CH’s of Arg, Gly, Asp, 3-Pal

1

H NMR spectra of Re(CO)3[pyta-Ala-Ala-Ala-Ala-3Pal] (3.10) in DMSO-d6 at 400 MHz

121

g-COSY NMR spectra of Re(CO)3[pyta-Ala-Ala-Ala-Ala-3Pal] (3.10) in DMSO-d6 at 400 MHz

Ar-H + NH of Alanine (1- 4), 3-Pal

CH3’s of Alanine (1- 4)
α CH’s

122

CH2 - 3Pal

NOESY NMR spectra of Re(CO)3[pyta-Ala-Ala-Ala-Ala-3Pal] (3.10) in DMSO-d6 at 400 MHz

Ar-H + NH of Alanine (1- 4), 3-Pal
α CH’s
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CH2 - 3Pal

CH3’s of Alanine (1- 4)

1

H NMR spectra of Re(CO)3[pyta-Ala-Ala-Ala-Ala-Ala-3Pal] (3.11) in DMSO-d6 at 400 MHz

124

g-COSY NMR spectra of Re(CO)3[pyta-Ala-Ala-Ala-Ala-Ala-3Pal] (3.11) in DMSO-d6 at 400
MHz

Ar-H + NH of Alanine (1- 5), 3-Pal

CH3’s of Alanine (1- 5)
α CH’s
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CH2 - 3Pal

NOESY NMR spectra of Re(CO)3[pyta-Ala-Ala-Ala-Ala-Ala-3Pal] (3.11) in DMSO-d6 at 400
MHz

Ar-H + NH of Alanine (1- 5), 3-Pal

CH3’s of Alanine (1- 5)
α CH’s
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CH2 - 3Pal

1

H NMR spectra of Re(CO)3[pyta-Ala-ala-Ala-3Pal] (3.12) in DMSO-d6 at 400 MHz

127

g-COSY NMR spectra of Re(CO)3[pyta-Ala-ala-Ala-3Pal] (3.12) in DMSO-d6 at 400 MHz

Ar-H + NH of Alanine (1- 3), 3-Pal

CH3’s of Alanine (1- 3)
α CH’s
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CH2 - 3Pal

NOESY NMR spectra of Re(CO)3[pyta-Ala-ala-Ala-3Pal] (3.12) in DMSO-d6 at 400 MHz

Ar-H + NH of Alanine (1- 3), 3-Pal
α CH’s
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CH3’s of Alanine (1- 3)
CH2 - 3Pal

1

H NMR spectra of Re(CO)3[Bipyd-Ala-Ala-Ala-3Pal] (3.13) in DMSO-d6 at 400 MHz

130

g-COSY NMR spectra of Re(CO)3[Bipyd-Ala-Ala-Ala-3Pal] (3.13) in DMSO-d6 at 400 MHz

CH3’s of Alanine (1- 3)

Ar-H + NH of Alanine (1- 3), 3-Pal
α CH’s
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CH2 - 3Pal

NOESY NMR spectra of Re(CO)3[Bipyd-Ala-Ala-Ala-3Pal] (3.13) in DMSO-d6 at 400 MHz

CH3’s of Alanine (1- 3)

Ar-H + NH of Alanine (1- 3), 3-Pal
α CH’s CH2 - 3Pal
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1

H NMR spectra of Re(CO)3[Bipyd-Arg-Gly-Asp-3Pal] (3.14) in DMSO-d6 at 400 MHz

133

g-COSY NMR spectra of Re(CO)3[Bipyd-Arg-Gly-Asp-3Pal] (3.14) in DMSO-d6 at 400 MHz

Ar-H + NH of Arg, Gly, Asp, 3-Pal

α CH’s of Arg, Gly, Asp, 3-Pal

134

Appendix C. Variable temperature NMR spectra

Re(CO)3[pyta-Arg-Gly-Asp-3pal] (3.9) in DMSO-d6 at 600 MHz from 25°- 60°C
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Re(CO)3[pyta-Ala-Ala-Ala-Ala-3pal] (3.10) in DMSO-d6 at 600 MHz from 25°- 60°C
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Re(CO)3[Bipyd-Arg-Gly-Asp-3pal] (3.14) in DMSO-d6 at 600 MHz from 25°- 60°C
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